WO2001045746A2 - Methods and compositions for prolonging elimination half-times of bioactive compounds - Google Patents
Methods and compositions for prolonging elimination half-times of bioactive compounds Download PDFInfo
- Publication number
- WO2001045746A2 WO2001045746A2 PCT/US2000/035325 US0035325W WO0145746A2 WO 2001045746 A2 WO2001045746 A2 WO 2001045746A2 US 0035325 W US0035325 W US 0035325W WO 0145746 A2 WO0145746 A2 WO 0145746A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- xaa
- peptide
- cys
- leu
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Definitions
- This invention relates to novel compounds tenned peptide ligands which bind a predetermined molecule such as a plasma protein.
- the invention relates to compositions comprising a hybrid molecule comprising a peptide ligand domain and an active domain such as a biologically active molecule.
- the active domain may comprise a molecule useful for diagnostic or therapeutic purposes.
- the hybrid compositions comprising the peptide ligand domain and active domain have improved pharmacokinetic or phannacological properties.
- the invention further provides for the research, diagnostic and therapeutic use of the peptide ligand and includes compositions such as pharmaceutical compositions comprising the peptide ligand molecules.
- Phage-display provides a means for generating constrained and unconstrained peptide libraries (Devlin et al, (1990) Science 249:404-406; Cwirla et al, (1990) Proc. Natl. Acad. Sci. USA 87:6378-6382; Lowman (1997) Ann. Rev. Biophys. Biomol. Struct. 26:401-424). These libraries can be used to identify and select peptide ligands that can bind a predetermined target molecule (Lowman (1997), supra); Clackson and Wells (1994) Trends Biotechnol. 12:173-184; Devlin et al, (1990) supra).
- IGFBPs insulin-like growth factor 1 binding proteins
- affinity or specificity improved proteins include human growth hormone, zinc fingers, protease inhibitors, atrial natriuretic factor, and antibodies (Wells, J. and Lowman H. (1992), Curr. Opin. Struct. Biol. 2:597-604; Clackson, T. and Wells, J. (1994), Trends Biotechnol. 12:173-184; Lowman et al, (1991) Biochemistry 30(10):832-838; Lowman and Wells J. (1993), /. Mol. Biol. 234:564-578; Dennis M. and Lazarus R. (1994), J. Biol. Chem. 269(22): 137- 144).
- the present invention provides novel compounds that bind to plasma proteins.
- the compounds of the present invention are, for example, peptides or peptide derivatives such as peptide mimetics and peptide analogs.
- the compounds are non-naturally occurring amino acid sequences that bind plasma proteins such as serum albumin or a portion of an immunoglobulin, as for example, IgG- Fc.
- the peptide ligand is a non-naturally occurring amino acid sequence of between about 10 and 20 amino acid residues.
- Such compounds preferably bind a desired plasma protein with an affinity characterized by a dissociation constant, K d , that is less than about 100 ⁇ M, preferably less than about 100 nM, and preferably do not substantially bind other plasma proteins.
- K d dissociation constant
- Specific examples of such compounds include linear or cyclic, especially cyclic peptides, preferably between about 10 and 20 amino acid residues in length, and combinations thereof, optionally modified at the N-terminus or C-terminus or both, as well as their salts and derivatives, functional analogues thereof and extended peptide chains carrying amino acids or polypeptides at the termini ofthe sequences.
- Preferred peptide ligands bind IgG-Fc and include linear and cyclic peptides, preferably cyclic peptide compounds comprising the following core formula: Xaai-Cys-Xaa,-Cys-Xaa k (SEQ ID NO: 1), wherein Xaaj is absent or is a peptide of between 1 and 4 amino acids, preferably 4 amino acids; Xj is preferably 9 amino acids having a preferred sequence Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Leu-Val-Trp (SEQ ID NO: 10); or Xaa-Xaa-Xaa-Xa-
- Xaa preferably is Ala, Ser, or Thr; Xaa 2 preferably is Trp or Tyr; Xaa 3 preferably is His, or Trp; Xaa 4 preferably is Leu or Met, and Xaa k is absent or between 1 and 5 amino acids, preferably 5 amino acids, so long as the cyclic peptide or analog thereof retains the qualitative biological activity of IgG-Fc binding.
- Preferred among this group of compounds are compounds that bind IgG-Fc comprising the sequence: Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Leu-Val-Trp-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Leu-Val-Trp-Cys-Xaa-Xaa-Xaa-Xa-Xa-Xa-
- Preferred peptide ligands that bind serum albumin include linear and cyclic peptides, preferably cyclic peptide compounds comprising the following formulae: (Xaa) x -Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-(Xaa) z
- the invention is directed to combinations of a peptide ligand with a bioactive compound to form a hybrid molecule that comprises a peptide ligand domain and an active domain.
- the bioactive compounds of the invention include any compound useful as a therapeutic or diagnostic agent.
- bioactive compounds include polypeptides such as enzymes, hormones, cytokines, antibodies or antibody fragments, as well as organic compounds such as analgesics, antipyretics, antiinflammatory agents, antibiotics, antiviral agents, anti-fungal drugs, cardiovascular drugs, drugs that affect renal function and electrolyte metabolism, drugs that act on the central nervous system and chemotherapeutic drugs, to name but a few.
- polypeptides such as enzymes, hormones, cytokines, antibodies or antibody fragments
- organic compounds such as analgesics, antipyretics, antiinflammatory agents, antibiotics, antiviral agents, anti-fungal drugs, cardiovascular drugs, drugs that affect renal function and electrolyte metabolism, drugs that act on the central nervous system and chemotherapeutic drugs, to name but a few.
- the hybrid molecules comprising a peptide ligand domain and an active domain have improved pharmacokinetic or pharmacodynamic properties as compared to the same bioactive molecule comprising the active domain but lacking the peptide ligand domain.
- the improved pharmacokinetic or pharmacodynamic properties of the hybrids thereby provide for low-dose pharmaceutical formulations and novel pharmaceutical compositions.
- the invention provides for methods of using the novel compositions including the therapeutic or diagnostic use ofthe hybrid molecules.
- the invention is directed to combinations of peptide ligands with bioactive compounds that have relatively short elimination half-times.
- the combinations are prepared with various objectives in mind, including improving the therapeutic or diagnostic efficacy of the bioactive compound in aspects of the invention involving in vivo use of the bioactive compound, by for example, increasing the elimination half-time of the bioactive compound.
- Fusing or linking i.e., "conjugating" the peptide ligand directed against a plasma protein such as serum albumin, an immunoglobulin, an apolipoprotein or transferrin to a bioactive compound provides compositions with increased elimination half-times.
- Such combinations or fusions are conveniently made in recombmant host cells, or by the use of bifunctional crosslinking agents.
- aspects of the invention include methods and compositions to purify antibodies using peptide ligands having binding affinity for immunoglobulins, such as, for example, the IgG- Fc peptide ligands disclosed herein.
- the present invention further extends to therapeutic and diagnostic applications for the compositions described herein. Therefore, the invention includes pharmaceutical compositions comprising a pharmaceutically acceptable excipient and the hybrid molecules ofthe invention.
- Phage competitive ELISA assay showing IgG binding of peptide-ligand tagged anti-VEGF Fab-phagemid particles.
- Four different constructs are shown: pY0192-569 (large filled circles), pY0192-570 (large open circles), PY0317-569 (small filled circles), and pY0317-570 ("x'"s).
- FIG. 2 BIAcoreTM analysis of IgG binding to peptide-ligand tagged anti-VEGF Fab Y0317-570 (tagged; top panel) Y0317 Fab (control; bottom panel).
- a cartoon illustration at top shows a rnodel for the binding events observed in the tagged Fab experiment.
- Fig. 4 The peptide sequences displayed by phage clones selected for binding to rabbit, human or rat albumin are shown in Figure 4. Also indicated is the ability of individual phage clones to bind the 3 species of immobilized albumin.
- FIG. 5 A and 5B Sequences identified following soft randomization are shown in Figure 5 along with their species specificity as determined by phage ELISA.
- Clones originating from the RB soft randomization library were found by ELISA to bind each of these species of albumin and were specific for albumin based upon their lack of binding to ovalbumin and casein.
- FIG. 8A, 8B and 8C Sequences from libraries selected against rat, rabbit and human albumin are shown in Figures 8 A, 8B, and 8C respectively.
- Fig. 9 Peptides corresponding to identified phage sequences were synthesized and their affinity for rat, rabbit or mouse albumin measured using the SA08b binding assay.
- Fig. 10 A peptides corresponding to the SA06 identified phage sequence was synthesized and its affinity for rat, rabbit or mouse albumin measured using the SAO 8b binding assay. Fig. 11. The SA06 sequence was added to the carboxy terminus of either the light chain
- D3H44-L or heavy chain (D3H44-Ls) of the Fab.
- identical constructs were made with the intra-chain disulfide replaced by alanines (D3H44-Ls and D3H44-Hs, respectively) as depicted in Figure 11.
- Fig. 12 Purified D3H44 fusions retained their ability to bind TF as measured using a FX activation assay.
- both D3H44-L and D3H44-Ls are able to bind to albumin as measured in the SA08b binding assay.
- Both D3H44 albumin-binding fusions are capable of binding TF and albumin simultaneously as judged by a biotin-TF binding assay.
- peptide ligand within the context of the present invention is meant to refer to non-naturally occurring amino acid sequences that function to bind a particular target molecule.
- Peptide ligands within the context of the present invention are generally constrained (that is, having some element of structure as, for example, the presence of amino acids which initiate a ⁇ turn or ⁇ pleated sheet, or for example, cyclized by the presence of disulfide-bonded Cys residues) or unconstrained (linear) amino acid sequences of less than about 50 amino acid residues, and preferably less than about 40 amino acids residues.
- peptide ligands less than about 40 amino acid residues, preferred are the peptide ligands of between about 10 and about 30 amino acid residues and especially the peptide ligands of about 20 amino acid residues.
- the skilled artisan will recognize that it is not the length of a particular peptide ligand but its ability to bind a particular target molecule that distinguishes the peptide ligand of the present invention. Therefore peptide ligands of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 25 amino acid residues, for example, are equally likely to be peptide ligands within the context ofthe present invention.
- a peptide ligand of the present invention will bind a target molecule with sufficient affinity and specificity if the peptide ligand "homes" to, “binds” or “targets” a target molecule such as a specific cell type bearing the target molecule in vitro and preferably in vivo (see, for example, the use of the term “homes to,” “homing,” and “targets” in Pasqualini and Ruoslahti (1996)
- the peptide ligand will bind a target molecule with an affinity characterized by a dissociation constant, K , of less than about 1 ⁇ M, preferably less than about 100 nM and more preferably less than about 10 nM.
- K dissociation constant
- peptide ligands having an affinity for a target molecule of less than about 1 nM and preferably between about 1 pM and 1 nM are equally likely to be peptide ligands within the context ofthe present invention.
- a peptide ligand that binds a particular target molecule as described above can be isolated and identified by any of a number of art-standard techniques as described herein.
- Peptides ligands are amino acid sequences as described above which may contain naturally as well as non-naturally occurring amino acid residues. Therefore, so-called “peptide mimetics” and “peptide analogs” which may include non-amino acid chemical structures that mimic the structure of a particular amino acid or peptide may be peptide ligands within the context of the invention.
- Such mimetics or analogs are characterized generally as exhibiting similar physical characteristics such as size, charge or hydrophobicity present in the appropriate spacial orientation as found in their peptide counterparts.
- a specific example of a peptide mimetic compound is a compound in which the amide bond between one or more of the amino acids is replaced by, for example, a carbon-carbon bond or other bond as is well known in the art (see, for example Sawyer, in Peptide Based Drug Design pp. 378-422 (ACS, Washington DC 1995)). Therefore, the term "amino acid" within the scope of the present invention is used in its broadest sense and is meant to include naturally occurring L ⁇ -amino acids or residues. The commonly used one and three letter abbreviations for naturally occurring amino acids are used herein (Lehninger, A.L., Biochemistry, 2d ed., pp. 71-92, (1975), Worth Publishers, New York).
- D ala
- C Cys
- D Asp
- E Glu
- F Phe
- G Gly
- H His
- I He
- K Lys
- L Leu
- M Met
- N Asn
- P Pro
- Q Gin
- R Arg
- S Ser
- T Thr
- V Val
- W Trp
- Y Tyr.
- the term includes D-amino acids as well as chemically modified amino acids such as amino acid analogs, naturally occurring amino acids that are not usually incorporated into proteins such as norleucine, and chemically synthesized compounds having properties known in the art to be characteristic of an amino acid.
- analogs or mimetics of phenylalanine or proline which allow the same conformational restriction of the peptide compounds as natural Phe or Pro are included within the definition of amino acid.
- Such analogs and mimetics are referred to herein as "functional equivalents" of an amino acid.
- Other examples of amino acids are listed by Roberts and Vellaccio The Peptides: Analysis, Synthesis, Biology, Gross and Meiehofer, eds., Vol. 5 p. 341, Academic Press, Inc., N.Y. 1983, which is incorporated herein by reference.
- Peptide ligands synthesized by, for example, standard solid phase synthesis techniques are not limited to amino acids encoded by genes.
- Commonly encountered amino acids which are not encoded by the genetic code include, for example, those described in International Publication No. WO 90/01940 such as, for example, 2-amino adipic acid (Aad) for Glu and Asp; 2-aminopimelic acid (Apm) for Glu and Asp; 2-aminobutyric (Abu) acid for Met, Leu, and other aliphatic amino acids; 2-aminoheptanoic acid (Alie) for Met, Leu and other aliphatic amino acids; 2- aminoisobutyric acid (Aib) for Gly; cyclohexylalanine (Cha) for Val, and Leu and He; homoarginine (Har) for Arg and Lys; 2,3-diaminopropionic acid (Dpr) for Lys, Arg and His; N- ethyl
- Peptide ligands within the context of the present invention may be "engineered", i.e., they are non-native or non-naturally occurring peptide ligands.
- non-native or “non-naturally occurring” is meant that the amino acid sequence of the particular peptide ligand is not found in nature. That is to say, amino acid sequences of non-native or non-naturally occurring peptide ligands do not correspond to an amino acid sequence of a naturally occurring protein or polypeptide.
- Peptide ligands of this variety may be produced or selected using a variety of techniques well known to the skilled artisan. For example, constrained or unconstrained peptide libraries may be randomly generated and displayed on phage utilizing art standard techniques, for example, Lowman et al, (1998) Biochemistry 37:8870-8878.
- Peptide ligands when used within the context of the present invention, may be "conjugated” to a therapeutic or diagnostic substance.
- the term “conjugated” is used in its broadest sense to encompass all methods of attachment or joining that are known in the art.
- the therapeutic or diagnostic substance is a protein (referred to herein as a "protein therapeutic")
- the peptide ligand will be an amino acid extension of the C- or N-terminus of the protein therapeutic.
- a short amino acid linker sequence may lie between the protein therapeutic and the peptide ligand.
- the peptide ligand, optional linker and protein therapeutic will be coded for by a nucleic acid comprising a sequence encoding protein therapeutic operably linked to (in the sense that the DNA sequences are contiguous and in reading frame) an optional linker sequence encoding a short polypeptide as described below, and a sequence encoding the peptide ligand.
- the peptide ligand is considered to be "conjugated" to the protein therapeutic optionally via a linker sequence.
- the peptide ligand amino acid sequence may interrupt or replace a section of the protein therapeutic amino acid sequence, provided, of course, that the insertion of the peptide ligand amino acid sequence does not interfere with the function of the protein therapeutic.
- the "conjugate” may be coded for by a nucleic acid comprising a sequence encoding protein therapeutic interrupted by and operably linked to a sequence encoding the peptide ligand.
- the peptide will be linked, e.g., by chemical conjugation to the protein therapeutic or other therapeutic optionally via a linker sequence.
- the peptide ligand will be linked to the protein therapeutic via a side chain of an amino acid somewhere in the middle of the protein therapeutic that doesn't interfere with the therapeutic 's activity.
- the peptide is considered to be "conjugated" to the therapeutic.
- target molecule includes, proteins, peptides, glycoproteins, glycopeptides, glycolipids, polysaccharides, oligosaccharides, nucleic acids, and the like.
- Target molecules include, for example, extracellular molecules such as various serum factors including but not limited to plasma proteins such as serum albumin, immunoglobulins, apolipoproteins or transferrin, or proteins found on the surface of erythrocytes or lymphocytes, provided, of course, that binding of the peptide ligand to the cell surface protein does not substantially interfere with the normal function ofthe cell.
- Antibodies and “immunoglobulins” are usually heterotetrameric glycoproteins of about 150,000 Daltons, composed of two identical light (L) chains and two identical heavy (H) chains.
- Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments or regions, each with a single antigen-binding site, and a residual "Fc” fragment or region.
- Fab antigen-binding fragments or regions
- Fc residual fragment or region.
- the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof.
- Pepsin treatment yields an F(ab')2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen.
- the Fab' fragment contains the constant domain of the light chain and the first constant domain (CHI) ofthe heavy chain.
- Treatment refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.
- mammal for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc. Preferably, the mammal is human.
- a “disorder” is any condition that would benefit from treatment with the compositions comprising the peptide ligands of the invention. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question.
- “Elimination half-time” is used in its ordinary sense, as is described in Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 21-25 (Alfred Goodman Gilman, Louis S. Goodman, and Alfred Gilman, eds., 6th ed. 1980). Briefly, the term is meant to encompass a quantitative measure of the time course of drug elimination.
- the elimination of most drugs is exponential (i.e., follows first-order kinetics), since drug concentrations usually do not approach those required for saturation ofthe elimination process.
- the rate of an exponential process may be expressed by its rate constant, k, which expresses the fractional change per unit of time, or by its half-time, ty 2 , the time required for 50% completion of the process. The units of these two constants are time"!
- Transfection refers to the taking up of an expression vector by a host cell whether or not any coding sequences are in fact expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, CaP04 precipitation and electroporation.
- Transfection means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integrant. Depending on the host cell used, transformation is done using standard techniques appropriate to such cells.
- pulmonary administration refers to administration of a formulation ofthe invention through the lungs by inhalation.
- inhalation refers to intake of air to the alveoli. In specific examples, intake can occur by self-administration of a formulation of the invention while inhaling, or by administration via a respirator, e.g. , to an patient on a respirator.
- respirator e.g. , to an patient on a respirator.
- inhalation used with respect to a formulation ofthe invention is synonymous with "pulmonary administration.”
- parenteral refers to introduction of a compound ofthe invention into the body by other than the intestines, and in particular, intravenous (i.v.), intraarterial (i.a.), intraperitoneal (i.p.), intramuscular (i.m.), intraventricular, and subcutaneous (s.c.) routes.
- an aerosol formulation is a formulation comprising a compound of the present invention that is suitable for aerosolization, i.e., particlization and suspension in the air, for inhalation or pulmonary administration.
- Peptide ligands within the context of the present invention bind a target, preferably a serum protein such as serum albumin or an immunoglobulin, and can be identified in a direct binding assay, or by their ability to compete for target binding with a known ligand for the target.
- Preferred peptide ligands that bind serum albumin include linear and cyclic peptides, preferably cyclic peptide compounds comprising the following formulae or are peptides that compete for binding serum albumin of a particular mammalian species with peptides ofthe following formulae:
- peptide ligands that bind a serum albumin are identified as described herein in the context of the following general formulae (Xaa) x -Trp-Cys-Asp-Xaa-Xaa-Leu-Xaa- Ala-Xaa-Asp-Leu-Cys-(Xaa) z and (Xaa) x - Asp-Leu- Val-Xaa-Leu-Gly-Leu-Glu-Cys-Trp-(Xaa) z wherein Xaa is an amino acid and x and z are a whole number greater or equal to zero, generally less than 100, preferably less than 10 and more preferably 0, 1, 2, 3, 4 or 5 and more preferably 4 or 5.
- Figures 5A and 5B, 8A, 8B and 8C and Figure 9 for exemplary peptides and appropriate amino acids for selecting peptides ligands that bind a mammalian serum albumin.
- Figure 9 for selecting peptide ligands that bind accross several species of serum albumin.
- Preferred compounds according to this aspect ofthe invention include: Asp-Leu-Cys-Leu-Arg-Asp-Trp-Gly-Cys-Leu-Trp (SEQ ID NO: zl)
- peptide ligands of the present invention bind IgG-Fc and can be identified by their ability to compete for binding of IgG-Fc in an in vitro assay with a peptide ligand having the general formula:
- Xaai-Cys-Xaaj-Cys-Xaak (SEQ ID NO: 1), wherein Xaaj is absent or is a peptide of between 1 and 4 amino acids, preferably 4 amino acids; Xi is preferably 9 amino acids having a preferred sequence Xaa-Xaa-Xaa-Xaa-Xaa-Xaa-Leu-Val-Trp (SEQ ID NO: 10); or Xaa-Xaa-Xaa- Xaa-Gly-Glu-Leu-Val-T ⁇ (SEQ HO NO: 11); or Xaa ⁇ -Xaa 2 -Xaa 3 -Xaa4-Gly-Glu-LeuNal-T ⁇ (SEQ ID NO: 12), wherein Xaaj is Ala, Ser, or Thr; Xaa 2 is T ⁇ or Tyr; Xaa 3 is His, or T ⁇ ; Xaa4 is Leu or Met, and Xa
- Preferred among this group of compounds are compounds comprising the sequence: Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Leu-Val-T ⁇ -Cys-Xaa-Xaa-Xaa- Xaa-Xaa (SEQ ID NO: 13); Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa-Xa-Xaa-Xaa-Gly-Glu-Leu-Val-T ⁇ -Cys-Xaa-Xaa-Xaa-Xaa-Xa-Xa-Xa-Xa-Xa-SEQ ID NO: 13); Xaa-Xaa-Xa-Xa-Cys-Xaa-Xaa-Xa-Xa-Xa-Gly-Glu-Leu-Val-T ⁇ -Cys-Xaa-Xaa-Xaa
- Xaa ⁇ o-X a ll-X a ai2-X aa 13 (SEQ ID NO: 16) wherein Xaa4 is Ser, Arg, or Asp; Xaa5 is Ala, Ser, or Thr; Xaag is T ⁇ , Tyr; Xaay is His, or T ⁇ ; Xaag is Leu or Met; and Xaao is Glu, Ser, Thr or Val.
- the IgG-Fc binding peptide ligands of the present invention will compete with any of the peptide ligands represented in SEQ ID NO: 3 - SEQ ED NO: 4, SEQ ID NO: 9; and SEQ ID NO: 13 - SEQ ID NO: 111 described herein and preferably will compete with SEQ ID NO: 9 for binding IgG-Fc.
- peptide ligands of the present invention bind human serum albumin and can be identified by their ability to compete for binding of human serum albumin in an in vitro assay with peptide ligands having the general formulae: (Xaa) x - Asp-Xaa-Cys-Leu-Pro-Xaa-T ⁇ -Gly-Cys-Leu-T ⁇ -(Xaa) z (Xaa) x -Phe-Cys-Xaa-Asp-T ⁇ -Pro-Xaa-Xaa-Xaa-Ser-Cys-(Xaa) z
- Xaa x -Cys-Tyr-Xaa ⁇ -Pro-Gly-Xaa-Cys-(Xaa) z
- Xaa is an amino acid
- x and z are preferably 4 or 5
- Xaai is selected from the group consisting of He, Phe, Tyr and Val.
- the human serum albumin binding peptide ligands of the present invention will compete with any ofthe peptide ligands represented in SEQ ID NO: z2 - zl4 described herein above and preferably will compete with SEQ ID NO: z4 for binding human serum albumin.
- the term "compete” and “ability to compete” are relative terms.
- the terms when used to describe the peptide ligands of the present invention, refer to peptide ligands that produce a 50% inhibition of binding of, for example SEQ ED NO: 9 or SEQ ID NO: z4, when present at 50 ⁇ M, preferably when present at 1 ⁇ M, more preferably 100 nM, and preferably when present at 1 nM or less in a standard competition assay as described herein.
- Such peptide ligands generally will bind IgG-Fc with an affinity of less than 1 ⁇ M, preferably less than about 100 nM and more preferably less than about 10 nM as determined by a standard competition assay such as the one described in the Example sections.
- peptide ligands having an affinity for a serum protein such as serum albumin or IgG-Fc of less than about 1 nM and preferably between about 1 pM and 1 nM are equally likely to be peptide ligands within the context ofthe present invention.
- a peptide or other compound may determine whether a peptide or other compound has the ability to compete with a peptide ligand for binding to an IgG-Fc (or other target such as a plasma protein) employing procedures which mclude but are not limited to competitive assay systems using techniques such as radioimmunoassays (RIA), enzyme immunoassays (EIA), preferably the enzyme linked immunosorbent assay (ELISA), "sandwich” immunoassays, immunoradiometric assays, fluorescent immunoassays, and immunoelectrophoresis assays, to name but a few.
- RIA radioimmunoassays
- EIA enzyme immunoassays
- ELISA enzyme linked immunosorbent assay
- "sandwich” immunoassays immunoradiometric assays
- fluorescent immunoassays or immunoelectrophoresis assays
- the selected peptide ligand will be labeled with a detectable moiety (the detectably labeled peptide ligand hereafter called the "tracer") and used in a competition assay with a candidate compound for binding IgG-Fc domain or other target.
- detectable labels are available which can be preferably grouped into the following categories: (a) Radioisotopes, such as 35s, ⁇ C, 125 . 3JJ, and 131l.
- the peptide compound can be labeled with the radioisotope using the techniques described in Coligen et al, eds., Current Protocols in Immunology, Volumes 1 and 2 (1991), Wiley-Interscience, New York, N.Y., for example and radioactivity can be measured using scintillation counting.
- Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, lissamine, phycoerythrin and Texas Red are available.
- the fluorescent labels can be conjugated to the peptide compounds using the techniques disclosed in Current Protocols in Immunology, supra, for example. Fluorescence can be quantified using a fluorimeter.
- the enzyme preferably catalyzes a chemical alteration of the chromogenic substrate which can be measured using various techniques.
- the enzyme may catalyze a color change in a substrate, which can be measured spectrophotometrically.
- the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above.
- the chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emitlight which can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor.
- enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRP), alkaline phosphatase, ⁇ -galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like.
- luciferases e.g., firefly luciferase and bacterial luciferas
- enzyme-substrate combinations include, for example:
- HRP Horseradish peroxidase
- a dye precursor e.g. ABTS, orthophenylene diamine (OPD) or 3,3',5,5'-tetramethyl benzidine hydrochloride (TMB)
- OPD orthophenylene diamine
- TMB 3,3',5,5'-tetramethyl benzidine hydrochloride
- ⁇ -D-galactosidase ( ⁇ -D-Gal) with a chromogenic substrate (e.g. p-nitrophenyl- ⁇ -D- galactosidase) or f ⁇ uorogenic substrate 4-methylumbelliferyl- ⁇ -D-galactosidase.
- a chromogenic substrate e.g. p-nitrophenyl- ⁇ -D- galactosidase
- f ⁇ uorogenic substrate 4-methylumbelliferyl- ⁇ -D-galactosidase 4-methylumbelliferyl- ⁇ -D-galactosidase.
- the tracer is incubated with immobilized target in the presence of varying concentrations of unlabeled candidate compound. Increasing concentrations of successful candidate compound effectively compete with binding of the tracer to immobilized target.
- the concentration of unlabeled candidate compound at which 50% of the maximally-bound tracer is displaced is referred to as the "IC50" and reflects the IgG binding
- binding affinity of a mutated (“mut") sequence was directly compared of a control ("con") peptide using methods described in B.C. Cunningham, D.G. Lowe, B. Li, B.D. Bennett, and J.A. Wells, EMBO J. 13:2508 (1994) and characterized by the parameter EC50. Assays were performed under conditions where EC5o(con)/EC5o(mut) will approximate Kd(con)/Kd(mut).
- the invention provides compounds "having the ability to compete" for target molecules such as IgG or human serum albumin binding in an in vitro assay as described.
- the compound has an IC50 for the target such as IgG or human serum albumin of less than 1 ⁇ M.
- Preferred among these compound are compounds having an IC50 of less than about
- the compounds display an IC50 for the target molecule such as IgG or human serum albumin of less than about 100 pM and more preferably less than about 10 pM.
- a preferred in vitro assay for the determination of a candidate compound's ability to compete with a peptide ligand described herein is as follows and is described more fully in the Examples.
- the candidate compound is a peptide.
- the ability of a candidate compound to compete with a labeled peptide ligand tracer for binding to IgG or human serum albumin is monitored using an ELISA. Dilutions of a candidate compound in buffer are added to microtiter plates coated with IgG or human serum albumin (as described in the Example Sections) along with tracer for 1 hr. The microtiter plate is washed with wash buffer and the amount of tracer bound to IgG or human serum albumin measured. B.
- the peptide ligand is optionally linked to a bioactive compound to form a hybrid molecule that comprises a peptide ligand domain and an active domain.
- the bioactive compounds of the invention include any compound useful as a therapeutic or diagnostic agent.
- bioactive compounds include polypeptides such as enzymes, hormones, cytokines, antibodies or antibody fragments, as well as organic compounds such as analgesics, antipyretics, antiinflammatory agents, antibiotics, antiviral agents, anti-fungal drugs, cardiovascular drugs, drugs that affect renal function and electrolyte metabolism, drugs that act on the central nervous system, chemotherapeutic drugs, etc.
- the peptide ligand domain is joined to an active domain, optionally via a flexible linker domain.
- the hybrid molecules of the present invention are constructed by combining a peptide ligand domain with a suitable active domain.
- the peptide ligand domain may be joined via its N- or C-terminus to the N- or C- terminus of the active domain.
- nucleic acid encoding a peptide ligand will be operably linked to nucleic acid encoding the active domain sequence, optionally via a linker domain.
- the construct encodes a fusion protein wherein the C-terminus of the peptide ligand is joined to the N-terminus of the active domain.
- fusions where, for example, the N-terminus of the peptide ligand is joined to the N- or C-terminus of the active domain also are possible.
- the peptide ligand domain may be inserted within the active domain molecule rather than being joined to the active domain at its N-or C-terminus. This configuration may be used to practice the invention so long as the functions of the peptide ligand domain and the active domain are preserved.
- a peptide ligand may be inserted into a non-binding light chain CDR of an immunoglobulin without interfering with the ability of the immunoglobulin to bind to its target.
- Regions of active domain molecules that can accommodate peptide ligand domain insertions may be identified empirically (i.e., by selecting an insertion site, randomly, and assaying the resulting conjugate for the function of the active domain), or by sequence comparisons amongst a family of related active domain molecules (e.g., for active domains that are proteins) to locate regions of low sequence homology. Low sequence homology regions are more likely to tolerate insertions of peptide ligands domains than are regions that are well-conserved.
- the three-dimensional structure may provide guidance as to peptide ligand insertion sites. For example, loops or regions with high mobility (i.e., large temperature or "B" factors) are more likely to accommodate peptide ligand domain insertions than are highly ordered regions of the structure, or regions involved in ligand binding or catalysis.
- the peptide ligand domain is optionally linked to the active domain via a linker.
- the linker component ofthe hybrid molecule ofthe invention does not necessarily participate in but may contribute to the function of the hybrid molecule. Therefore, according to the present invention, the linker domain, is any group of molecules that provides a spatial bridge between the active domain and the peptide ligand domain.
- the linker domain can be of variable length and makeup, however, according to the present invention, it is the length of the linker domain and not its structure that is important.
- the linker domain preferably allows for the peptide ligand domain of the hybrid molecule to bind, substantially free of steric and/or conformational restrictions to the target molecule. Therefore, the length of the linker domain is dependent upon the character ofthe two "functional" domains of the hybrid molecule, i.e., the peptide ligand domain and the active domain.
- the linker domain may be a polypeptide of variable length.
- the amino acid composition of the polypeptide determines the character and length of the linker.
- the linker molecule comprises a flexible, hydrophilic polypeptide chain.
- Exemplary, linker domains comprises one or more Gly and or Ser residues, such as those described in the Example sections herein.
- the present invention encompasses a composition of matter comprising an isolated nucleic acid, preferably DNA, encoding a peptide ligand or a hybrid molecule comprising a peptide ligand domain and a polypeptide active domain as described herein.
- DNAs encoding the peptides of the invention can be prepared by a variety of methods known in the art. These methods include, but are not limited to, chemical synthesis by any of the methods described in Engels et al. (1989), Agnew. Chem. Int. Ed. Engl. 28:716-734, the entire disclosure of which is inco ⁇ orated herein by reference, such as the triester, phosphite, phosphoramidite and H-phosphonate methods.
- codons preferred by the expression host cell are used in the design of the encoding DNA.
- DNA encoding the peptides of the invention can be altered to encode one or more variants by using recombinant DNA techniques, such as site specific mutagenesis (Kunkel et al. (1991), Methods Enzymol, 204:125-139; Carter et al (1986), Nucl Acids Res. 13:4331; Zoller et al (1982), Nucl. Acids Res. 10:6487), cassette mutagenesis (Wells et al. (1985), Gene 34:315), restriction selection mutagenesis (Carter, Directed Mutagenesis: A Practical Approach (M.J. McPherson, ed.) IRL Press, Oxford, 1991), and the like.
- the nucleic acid encodes a peptide ligand capable of binding a target molecule.
- Target molecules include, for example, extracellular molecules such as various serum factors including but not limited to plasma proteins such as serum albumin, immunoglobulins, apolipoproteins or transferrin, or proteins found on the surface of erythrocytes or lymphocytes, provided, of course, that binding of the peptide ligand to the cell surface protein does not substantially interfere with the normal function ofthe cell.
- the nucleic acid encodes a hybrid molecule comprising a peptide ligand domain sequence and an active domain.
- the active domain may comprise any polypeptide compound useful as a therapeutic or diagnostic agent, e.g., enzymes, hormones, cytokines, antibodies or antibody fragments.
- the nucleic acid molecule according to this aspect of the present invention encodes a hybrid molecule and the nucleic acid encoding the peptide ligand domain sequence is operably linked to (in the sense that the DNA sequences are contiguous and in reading frame) the nucleic acid encoding the biologically active agent.
- these DNA sequences may be linked through a nucleic acid sequence encoding a linker domain amino acid sequence.
- the invention further comprises an expression control sequence operably linked to the DNA molecule encoding a peptide of the invention, an expression vector, such as a plasmid, comprising the DNA molecule, wherein the control sequence is recognized by a host cell transformed with the vector, and a host cell transformed with the vector.
- plasmid vectors contain replication and control sequences which are derived from species compatible with the host cell.
- the vector ordinarily carries a replication site, as well as sequences which encode proteins that are capable of providing phenotypic selection in transformed cells.
- suitable vectors include pBR322 (ATCC No. 37,017), phGH107 (ATCC No.
- Prokaryotic host cells containing the expression vectors of the present invention include E. coli K12 strain 294 (ATCC NO. 31,446), E. coli strain JMIOI (Messing et ⁇ /.(1981), Nucl. Acid Res. 9:309), E. coli strain B, E. coli strain _1776 (ATCC No. 31537), E.
- E. coli c600 E. coli W3110 (F-, gamma-, prototrophic, ATCC No. 27,325), E. coli strain 27C7 (W3110, tonA, phoA E15, (argF-lac)169, ptr3, degP41, ompT, kan r ) (U.S. Patent No. 5,288,931, ATCC No. 55,244), Bacillus subtilis, Salmonella typhimurium, Serratia marcesans, and Pseudomonas species.
- eukaryotic organisms such as yeasts, or cells derived from multicellular organisms can be used as host cells.
- suitable vectors include episomally- replicating vectors based on the 2-micron plasmid, integration vectors, and yeast artificial chromosome (YAC) vectors.
- yeast host cells such as common baker's yeast or Saccharomyces cerevisiae
- suitable vectors include episomally- replicating vectors based on the 2-micron plasmid, integration vectors, and yeast artificial chromosome (YAC) vectors.
- yeast host cells such as common baker's yeast or Saccharomyces cerevisiae
- suitable vectors include episomally- replicating vectors based on the 2-micron plasmid, integration vectors, and yeast artificial chromosome (YAC) vectors.
- yeast artificial chromosome e.g., baculoviral vectors.
- suitable expression vectors include vectors derived from the Ti plasmid of
- Examples of useful mammalian host cells include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al. (1977), J. Gen Virol. 36:59); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin (1980), Proc. Natl. Acad. Sci. USA 77:4216); mouse sertoli cells (TM4, Mather (1980), Biol. Reprod.
- COS-7 monkey kidney CV1 line transformed by SV40
- human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al. (1977), J. Gen Virol. 36:59
- baby hamster kidney cells BHK, ATCC CCL 10
- Chinese hamster ovary cells/-DHFR CHO, Urlaub and Chasin (1980), Proc. Natl.
- monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3 A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al. (1982), Annals NY. Acad. Sci. 383:44-68); MRC 5 cells; FS4 cells; and a human hepatoma cell line (Hep G2).
- useful vectors include vectors derived from SV40, vectors derived from cytomegalovirus such as the pRK vectors, including pRK5 and pRK7 (Suva et al. (1987), Science 237:893-896; EP 307,247 (3/15/89), EP 278,776 (8/17/88)) vectors derived from vaccinia viruses or other pox viruses, and retroviral vectors such as vectors derived from Moloney's murme leukemia virus (MoMLV).
- pRK vectors including pRK5 and pRK7 (Suva et al. (1987), Science 237:893-896; EP 307,247 (3/15/89), EP 278,776 (8/17/88) vectors derived from vaccinia viruses or other pox viruses
- retroviral vectors such as vectors derived from Moloney's murme leukemia virus (MoMLV).
- the DNA encoding the peptide of interest is operably linked to a secretory leader sequence resulting in secretion of the expression product by the host cell into the culture medium.
- secretory leader sequences include STII, ecotin, lamB, he ⁇ es GD, lpp, alkaline phosphatase, invertase, and alpha factor.
- secretory leader sequences include STII, ecotin, lamB, he ⁇ es GD, lpp, alkaline phosphatase, invertase, and alpha factor.
- secretory leader sequences include STII, ecotin, lamB, he ⁇ es GD, lpp, alkaline phosphatase, invertase, and alpha factor.
- 36 amino acid leader sequence of protein A Abrahmsen et al. (1985), EMBO J. 4:3901).
- Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
- Prokaryotic host cells used to produce the present peptides can be cultured as described generally in Sambrook et al, supra.
- the mammalian host cells used to produce peptides of the invention can be cultured in a variety of media.
- Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells.
- any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as GentamycinTM drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
- the culture conditions such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- the host cells referred to in this disclosure encompass cells in in vitro culture as well as cells that are within a host animal.
- Peptide ligands of the invention can be prepared conveniently using solid-phase peptide synthesis. Merrifield (1964), J. Am. Chem. Soc. 85:2149; Houghten (1985), Proc. Natl. Acad. Sci. USA 82:5132. Solid-phase peptide synthesis also can " be used to prepare the hybrid molecule compositions ofthe invention if the active domain is or comprises a polypeptide. Solid-phase synthesis begins at the carboxy terminus of the nascent peptide by coupling a protected amino acid to an inert solid support.
- the inert solid support can be any macromolecule capable of serving as an anchor for the C-terminus of the initial amino acid.
- the macromolecular support is a cross-linked polymeric resin (e.g., a polyamide or polystyrene resin) as shown in Figures 1-1 and 1-2, on pages 2 and 4 of Stewart and Young, supra.
- the C-terminal amino acid is coupled to a polystyrene resin to form a benzyl ester.
- a macromolecular support is selected such that the peptide anchor link is stable under the conditions used to deprotect the ⁇ -amino group of the blocked amino acids in peptide synthesis. If a base- labile ⁇ -protecting group is used, then it is desirable to use an acid-labile link between the peptide and the solid support.
- an acid-labile ether resin is effective for base-labile Fmoc- amino acid peptide synthesis as described on page 16 of Stewart and Young, supra.
- a peptide anchor link and ⁇ -protecting group that are differentially labile toacidolysis can be used.
- an aminomethyl resin such as the phenylacetamidomethyl (Pam) resin works well in conjunction with Boc-amino acid peptide synthesis as described on pages 11-12 of Stewart and Young, supra.
- the ⁇ -amino protecting group of the initial amino acid is removed with, for example, trifluoroacetic acid (TFA) in methylene chloride and neutralized in, for example, triethylamine (TEA).
- TFA trifluoroacetic acid
- TAA triethylamine
- ⁇ -amino and, if necessary, side chain protected amino acids are then coupled sequentially in the desired order by condensation to obtain an intermediate compound connected to the solid support.
- some amino acids may be coupled to one another to form a fragment of the desired peptide followed by addition of the peptide fragment to the growing solid phase peptide chain.
- the condensation reaction between two amino acids, or an amino acid and a peptide, or a peptide and a peptide can be carried out according to the usual condensation methods such as the axide method, mixed acid anhydride method, DCC (N,N'-dicyclohexylcarbodiimide) or DIC (N,N'-diisopropylcarbodiimide) methods, active ester method, p-nitrophenyl ester method, BOP (benzotriazole-1-yl-oxy-tris [dimethylamino] phosphonium hexafluorophosphate) method, N- hydroxysuccinic acid imido ester method, etc., and Woodward reagent K method.
- the axide method mixed acid anhydride method
- DCC N,N'-dicyclohexylcarbodiimide
- DIC N,N'-diisopropylcarbodiimide
- active ester method p-nitrophenyl
- benzyloxycarbonyl (abbreviated Z), isonicotinyloxycarbonyl (iNOC), o-chlorobenzyloxycarbonyl [Z(2C1)], p-nitrobenzyloxycarbonyl [Z(N ⁇ 2)], p-methoxybenzyloxycarbonyl [Z(OMe)], t-butoxycarbonyl (Boc), t-amyloxycarbonyl (Aoc), isobornyloxycarbonyl, adamantyloxycarbonyl, 2-(4-biphenyl)-2-propyloxycarbonyl (Bpoc),
- guanidino group of arginine may be protected with nitro, p-toluenesulfonyl, benzyloxycarbonyl, adamantyloxycarbonyl, p-methoxybenzesulfonyl, 4- methoxy-2,6-dimethylbenzenesulfonyl (Nds), 1,3,5-trimethylphenysulfonyl (Mts), and the like.
- the thiol group of cysteine can be protected with p-methoxybenzyl, trityl, and the like.
- the peptide is cleaved away from the solid phase by acidolysis with liquid hydrofluoric acid (HF), which also removes any remaining side chain protective groups.
- HF liquid hydrofluoric acid
- the acidolysis reaction mixture contains thio-cresol and cresol scavengers.
- the resin is washed with ether, and the free peptide is extracted from the solid phase with sequential washes of acetic acid solutions. The combined washes are lyophilized, and the peptide is purified.
- the hybrid molecules may comprise active domains that are organic compounds having diagnostic or therapeutic utility, or alternatively, fusions between a peptide ligand domain and a polypeptide active domain in configurations that cannot be encoded in a single nucleic acid.
- active domains that are organic compounds having diagnostic or therapeutic utility, or alternatively, fusions between a peptide ligand domain and a polypeptide active domain in configurations that cannot be encoded in a single nucleic acid. Examples of the latter embodiment include fusions between the amino terminus of a peptide ligand and the amino terminus of the active domain, or fusions between the carboxy-terminus of a peptide ligand and the carboxy- terminus ofthe active domain.
- Chemical conjugation may be employed to prepare these embodiments of the hybrid molecule, using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2- pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis- diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene, 2,6-diisocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4- dinitrobenzene).
- SPDP N-succin
- some embodiments of the invention include cyclized peptide ligands.
- Peptide ligands may be cyclized by formation of a disulfide bond between cysteine residues.
- Such peptides can be made by chemical synthesis as described above and then cyclized by any convenient method used in the formation of disulfide linkages.
- peptides can be recovered from solid phase synthesis with sulfhydryls in reduced form, dissolved in a dilute solution wherein the intramolecular cysteine concentration exceeds the intermolecular cysteine concentration in order to optimize intramolecular disulfide bond formation, such as a peptide concentration of 25 mM to 1 ⁇ M, and preferably 500 ⁇ M to 1 ⁇ M, and more preferably 25 ⁇ M to 1 ⁇ M, and then oxidized by exposing the free sulfhydryl groups to a mild oxidizing agent that is sufficient to generate intramolecular disulfide bonds, e.g., molecular oxygen with or without catalysts such as metal cations, potassium ferricyanide, sodium tetrathionate, etc.
- the peptides can be cyclized as described in Pelton et al. (1986), J. Med. Chem. 29:2370-2375.
- Cyclization can be achieved by the formation, for example, of a disulfide bond or alactam bond between a first Cys and a second Cys.
- Residues capable of forming a disulfide bond include, for example, Cys, Pen, Mpr, and Mpp and its 2-amino group-containing equivalents.
- Residues capable of forming a lactam bridge include, for example, Asp Glu, Lys, Orn, ⁇ -diaminobutyric acid, diaminoacetic acid, aminobenzoic acid and mercaptobenzoic acid.
- the compounds herein can be cyclized for example via a lactam bond which can utilize the side chain group of a non- adjacent residue to form a covalent attachment to the N-terminus amino group of Cys or other amino acid.
- Alternative bridge structures also can be used to cyclize the compounds of the invention, including for example, peptides and peptidomimetics, which can cyclize via S-S, CH2- S, CH2-0-CH2, lactam ester or other linkages.
- compositions which comprise the hybrid molecules of the invention may be administered in any suitable mamier, including parental, topical, oral, or local (such as aerosol or transdermal) or any combination thereof.
- suitable compositions of the present invention comprise any of the above-noted compositions with a pharmaceutically acceptable carrier, the nature ofthe carrier differing with the mode of administration, for example, in oral administration, usually using a solid carrier and ini.v. administration, a liquid salt solution carrier.
- compositions of the present invention include pharmaceutically acceptable components that are compatible with the subject and the protein of the invention. These generally include suspensions, solutions and elixirs, and most especially biological buffers, such as phosphate buffered saline, saline, Dulbecco's Media, and the like. Aerosols may also be used, or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like (in the case of oral solid preparations, such as powders, capsules, and tablets).
- biological buffers such as phosphate buffered saline, saline, Dulbecco's Media, and the like.
- Aerosols may also be used, or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like (in the case of oral solid preparations, such as powders
- the term "pharmaceutically acceptable” generally means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- the formulation of choice can be accomplished using a variety of the aforementioned buffers, or even excipients including, for -example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like.
- "PEGylation" of the compositions may be achieved using techniques known to the art (see for example International Patent Publication No. W092/16555, U.S. Patent No. 5,122,614 to Enzon, and International Patent Publication No. WO92/00748).
- a preferred route of administration of the present invention is in the aerosol or inhaled form.
- the compounds of the present invention, combined with a dispersing agent, or dispersant can be administered in an aerosol formulation as a dry powder or in a solution or suspension with a diluent.
- the term "dispersant” refers to a agent that assists aerosolization of the compound or abso ⁇ tion of the protein in lung tissue, or both.
- the dispersant is pharmaceutically acceptable.
- Suitable dispersing agents are well known in the art, and include but are not limited to surfactants and the like.
- surfactants that are generally used in the art to reduce surface induced aggregation of a compound, especially a peptide compound, caused by atomization of the solution forming the liquid aerosol, may be used.
- Nonlimiting examples of such surfactants are surfactants such as polyoxyethylene fatty acid esters and alcohols, and polyoxyethylene sorbitan fatty acid esters.
- Amounts of surfactants used will vary, being generally within the range of from about 0.001% to about 4% by weight of the formulation.
- the surfactant is polyoxyethylene sorbitan monooleate or sorbitan trioleate.
- Suitable surfactants are well known in the art, and can be selected on the basis of desired properties, depending on the specific formulation, concentration of the compound, diluent (in a liquid formulation) or form of powder (in a dry powder formulation), etc.
- the liquid or dry formulations can comprise additional components, as discussed further below.
- the liquid aerosol formulations generally contain the peptide ligand active domain hybrid and a dispersing agent in a physiologically acceptable diluent.
- the dry powder aerosol formulations of the present invention consist of a finely divided solid form of the peptide ligand/active domain hybrid and a dispersing agent. With either the liquid or dry powder aerosol formulation, the formulation must be aerosolized. That is, it must be broken down into liquid or solid particles in order to ensure that the aerosolized dose actually reaches the alveoli.
- the mass median dynamic diameter will be 5 micrometers or less in order to ensure that the drug particles reach the lung alveoli (Wearley, L.L. (1991), Crit. Rev. in Ther. Drug Carrier Systems 8:333).
- aerosol particle is used herein to describe the liquid or solid particle suitable for pulmonary administration, i.e., that will reach the alveoli.
- Other considerations such as construction of the delivery device, additional components in the formulation and particle characteristics are important.
- any form of aerosolization known in the art including but not limited to nebulization, atomization or pump aerosolization of a liquid formulation, and aerosolization of a dry powder formulation, can be used in the practice of the invention.
- a delivery device that is uniquely designed for administration of solid formulations is envisioned.
- the aerosolization of a liquid or a dry powder formulation will require a propellant.
- the propellant may be any propellant generally used in the art.
- Such useful propellants are a chloroflourocarbon, a hydrofluorocarbon, a hydochlorofluorocarbon, or a hydrocarbon, including triflouromethane, dichlorodiflouromethane, dichlorotetrafuoroethanol, and 1,1,1,2-tetraflouroethane, or combinations thereof.
- the device for aerosolization is a metered dose inhaler.
- a metered dose inhaler provides a specific dosage when administered, rather than a variable dose depending on administration.
- Such a metered dose inhaler can be used with either a liquid or a dry powder aerosol formulation.
- Metered dose inhalers are well known in the art.
- a number of formulation-dependent factors affect the drug abso ⁇ tion. It will be appreciated that in treating a disease or disorder that requires circulatory levels of the compound, such factors as aerosol particle size, aerosol particle shape, the presence or absence of infection, lung disease or emboli may affect the abso ⁇ tion of the compounds.
- certain lubricators, abso ⁇ tion enhancers, protein stabilizers or suspending agents may be appropriate. The choice of these additional agents will vary depending on the goal. It will be appreciated that in instances where local delivery of the compounds is desired or sought, such variables as abso ⁇ tion enhancement will be less critical.
- the liquid aerosol formulations of the present invention will typically be used with a nebulizer.
- the nebulizer can be either compressed air driven or ultrasonic. Any nebulizer known in the art can be used in conjunction with the present invention such as but not limited to:
- the formulation may include a carrier.
- the carrier is a macromolecule which is soluble in the circulatory system and which is physiologically acceptable where physiological acceptance means that those of skill in the art would accept injection of said carrier into a patient as part of a therapeutic regime.
- the carrier preferably is relatively stable in the circulatory system with an acceptable elimination half-time.
- macromolecules include but are not limited to soya lecithin, oleic acid and sorbetan trioleate, with sorbitan trioleate preferred.
- the formulations of the present embodiment may also include other agents useful for protein stabilization or for the regulation of osmotic pressure.
- agents include but are not limited to salts, such as sodium chloride, or potassium chloride, and carbohydrates, such as glucose, galactose or mannose, and the like.
- the present pharmaceutical formulation will be used as a dry powder inhaler formulation comprising a finely divided powder form of the peptide ligand and a dispersant.
- the form ofthe compound will generally be a lyophilized powder. Lyophilized forms of peptide ligand/active domain hybrid compounds can be obtained through standard techniques.
- the dry powder formulation will comprise a finely divided dry powder containing one or more compounds of the present invention, a dispersing agent and also a bulking agent. Bulking agents useful in conjunction with the present formulation include such agents as lactose, sorbitol, sucrose, or mannitol, in amounts that facilitate the dispersal of the powder from the device.
- the peptide ligands or the hybrid molecules of the invention are non-covalently adsorbed or covalently bound to a macromolecule, such as a solid support. It will be appreciated that the invention encompasses macromolecules complexed with the peptide ligands or hybrid molecules.
- the peptide ligands of the invention are directed against an immunoglobulin, such as, e.g., the IgG-Fc peptide ligands disclosed infra. Such peptide ligands may ,be used as affinity purification agents.
- the peptide ligands are immobilized on a solid phase support such as a Sephadex resin or filter paper, using methods well known in the art.
- the immobilized peptide ligand is contacted with a sample containing the immunoglobulin protein (or fragment thereof) to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the immunoglobulin protein, which is bound to the immobilized peptide ligand. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, that will release the immunoglobulin protein from the peptide ligand.
- a suitable solvent such as glycine buffer, pH 5.0
- the solid support is an inert matrix, such as a polymeric gel, comprising a three- dimensional structure, lattice or network of a material.
- a polymeric gel comprising a three- dimensional structure, lattice or network of a material.
- any macromolecule, synthetic or natural can form a gel in a suitable liquid when suitably cross-linked with a bifunctional reagent.
- the macromolecule selected is convenient for use in affinity chromatography.
- Most chromatographic matrices used for affinity chromatography are xerogels. Such gels shrink on drying to a compact solid comprising only the gel matrix. When the dried xerogel is resuspended in the liquid, the gel matrix imbibes liquid, swells and returns to the gel state.
- Xerogels suitable for use herein include polymeric gels, such as cellulose, cross-linked dextrans (e.g. Sepharose), agarose, cross-linked agarose, polyacrylamide gels, and poly
- aerogels can be used for affinity chromatography. These gels do not shrink on drying but merely allow penetration of the surrounding air. When the dry gel is exposed to liquid, the latter displaces the air in the gel. Aerogels suitable for use herein include porous glass and ceramic gels.
- peptide ligands or hybrid molecules of the invention coupled to derivatized gels wherein the derivative moieties facilitate the coupling of the hybrid molecules to the gel matrix and avoid steric hindrance of the peptide ligand-target molecule interaction in affinity chromatography.
- spacer arms can be inte ⁇ osed between the gel matrix and the hybrid molecules for similar benefits.
- the gene encoding a peptide ligand is associated, in a vector, with a gene encoding another protein or a fragment of another protein. This results in the peptide ligand being produced by the host cell as a fusion with another protein or peptide.
- the "other" protein or peptide is often a protein or peptide which can be secreted by the cell, making it possible to isolate and purify the other protein from the culture medium and eliminating the necessity of destroying the host cells which arises when the other protein remains inside the cell.
- the fusion protein can be expressed mtracellularly. It is useful to use fusion proteins that are highly expressed.
- peptide ligands which bind serum albumin are use as "affinity handles" for the purification of fused proteins on a solid serum albumin support.
- a DNA sequence encoding the desired peptide ligand can be fused by site directed mutagenesis to the gene for protein. After expression and secretion, the fusion protein can be purified on amatix of serum albumin to which the peptide ligand will bind.
- the peptide ligand can be enzymatically or chemically cleaved to yield free protein or left intact to aid in increasing the elimination half life of the fused protein.
- Fusion proteins can be cleaved using chemicals, such as cyanogen bromide, which cleaves at a methionine, or hy ⁇ oxylamine, which cleaves between an Asn and Gly residue.
- the nucleotide base pairs encoding these amino acids may be inserted just prior to the 5' end of the gene encoding the desired peptide.
- one can employ proteolytic cleavage of fusion protein. Carter, in Protein Purification: From Molecular Mechanisms to Large-Scale Processes, Ladisch et al., eds. (American Chemical Society Symposium Series No. 427, 1990), Ch 13, pages 181-193.
- IgG-Fc Peptide Ligands An in vitro selection designed to identify peptide ligands which bind the IgG-Fc surface without the constraint that the peptides function in vivo was performed. The selection was accomplished using a combination of polyvalent and monovalent phage display which has recently been applied to generate peptides that bind a variety of cellular hormones and receptors. N. C. Wrighton, et al (1996), Science 273:458, O. Livnah, et al. (1996), Science 273:464. A single
- This library was expressed on the surface of Ml 3 bacteriophage as an N-terminal fusion to the gene VIII protein with a short linker consisting of glycine and serine residues.
- peptides could be selected that bind to potentially any region of the IgG-Fc due to the unbiased nature of this library.
- Fc-I Glu-Thr-Gln-Arg-Cys-Thr-T ⁇ -His-Met-Gly-Glu-
- Fc-II (Lys-Glu-Ala-Ser-Cys-Ser-Tyr-T ⁇ -Leu-Gly-Glu-Leu-Val-T ⁇ -Cys-Val-Ala-Gly-Val-Glu) (SEQ ID NO: 4).
- the Fc-II peptide shared the cysteine spacing and the internal Gly-Glu-Leu-Val-T ⁇ (SEQ ID NO: 134) sequence seen in Fc-I.
- these two peptides bound IgG-Fc with an affinity high enough to be selected over any of the other IgG-Fc binding peptides present in the starting pool.
- Both peptides were synthesized on solid phase using standard 9- fluorenylmethoxycarbonyl protocols and purified by reversed-phase HPLC. Masses were confirmed by electrospray mass spectrometry, and purified peptides were quantified by UV absorbance at 280 nm.
- the DNA sequence of the Fc-II peptide was moved to a monovalent phage display format by cassette mutagenesis to give a construct with the STII signal sequence, the Fc-II peptide Lys- Glu-Ala-Ser-Cys-Ser-Tyr-T ⁇ -Leu-Gly-Glu-Leu-Val-T ⁇ -Cys-Val-Ala-Gly-Val-Glu (SEQ ID NO: 4), a Gly-Gly-Gly-Pro-Gly-Gly-Gly linker (SEQ ID NO: 5), and the M13 gene III protein starting at residue 253.
- the Fc-II sequence was affinity-matured by monovalent phage display. Five residue blocks were randomly mutated in six separate libraries to exhaustively cover the non- cysteine positions in the peptide sequence and then screened against IgG-Fc.
- a series of second generation monovalent phage display libraries were constructed based on the Fc-II sequence Lys-Glu-Ala-Ser-Cys-Ser-Tyr-T ⁇ -Leu-Gly-Glu-Leu-Val-T ⁇ -Cys-Val-Ala- Gly-Val-Glu (SEQ ID NO: 4) in which five sequential residues were randomized using NNS codons in each library starting at positions 1, 4, 7,10, 12, and 16, excluding the two cysteines. o Each library had a diversity of approximately 1x10 . These libraries were independently screened for binding to IgG-Fc for six rounds and then sequenced.
- Preferred residues from this selection were then recombined using three additional libraries that spanned the entire peptide sequence.
- the three additional libraries were constructed using the degeneracy of the genetic code to recombine the preferred amino acids at each position into one peptide.
- the DNA sequences for these libraries contained the following mixtures of bases (IUPAC codes): DRG GWA GMA RRC TGC KCT TRS CAC MTG GGC GAG CTG GTC TGG TGC RVC RVM BKC GAS KDW (SEQ ED NO: 6), DRS VWG SVG RRC TGC KCC TRS YRS MTG GGC GAG CTG GTC TGG TGC RNC WS NBS GWS KDM (SEQ ED NO: 7), and DNS NNS NNS VNS TGC BVG TDS HRS MDS GGC GAG STC KKG WRG TGC RNM NNS NNS NNS NNM (SEQ ED NO: 8). These libraries also were sorted against IgG-Fc for six rounds and then sequenced.
- Fahnestock et al. in Bacterial Hnmunoglobulin-Binding Proteins (Academic Press, Inc. 1990) Vol. 1, chap. 11. R. Karlsson, L. Jendeberg,' B. Nilsson, J. Nilsson, P. Nygren (1995), J. Immuno. Methods 183:43.
- Table I lists the amino acid sequences and IgG-Fc binding affinities of exemplary IgG-Fc peptide ligands that were identified using the procedures described above.
- KEASCSYWLGELVWCVAGVE SEQ ID NO: 4 5000 nM (Kj) ETQRCTWHMGELVWCEREHN SEQ HD NO: 3 5000 nM (Kj) DLADCSWHMGELVWCSRVEG SEQ ID NO: 17 50 nM (K ) WEADCAWHLGELVWCTPMEF SEQ ID NO: 18 30 nM (IC 50 ) DCAWHLGELVWCT SEQ ED NO: 9 100 nM (IC 50 )
- N/A Not individually assayed. Since they were selected for binding, EC50 likely to be ⁇ 1 uM or better.
- KEASCSYWLGELVWCDTLTE SEQ ED NO: 19 N/A KEASCSYWLGELVWCSPGVE SEQ ED NO: 20 734 nM KEASCSYWLGELVWCSGVEG SEQ ro NO: 21 N/A KEASCSYWLGELVWCSAGVE SEQ ID NO: 22 N/A Sequence Sequence DD NO Binding Affinity
- AVSKCSFHMGELVWCSDVMN SEQ ID NO: 54 N/A
- DLADCSWHLGELVWCSRVEG SEQ ID NO: 62 9 nM
- DLADCSWHLGELVWCVGLDE SEQ ID NO: 63 28 nM
- WVEDCSWHLGELVWCVGLDF SEQ ID NO: 64 31 nM
- EQADCAWHLGELVWCTPMVF SEQ ID NO: 81 8 nM
- GEQDCSYHMGELVWCTTVDG SEQ ID NO: 84 210 nM
- IgG-Fc peptide ligands may be combined with a bioactive compound to form a hybrid molecule that comprises a peptide ligand domain and an active domain.
- IgG-Fc peptide ligands are combined with a Fab fragment that recognizes human VEGF.
- a neutralizing antibody to human VEGF has been previously identified from murine hybridoma, humanized, and optimized by phage display. See Muller et al (1998), Structure 6:1153-1167; Chen et al (1999), J. Mol. Biol 293:865-881; and International Patent Publication No. WO 98/45331.
- Two humanized Fab forms of this antibody were chosen to test whether binding affinity to an irrelevant IgG could be added to the Fabs without disrupting their antigen-binding affinity.
- An IgG-Fc peptide ligand, DCAWHLGELVWCT (SEQ ED NO: 9), identified and optimized by the peptide- phage display method described in Example 1 was used, along with a short peptide linker (Gly- Gly-Gly) to provide flexibility between the peptide and the Fab.
- the light chain of the Fab was chosen for fusions because in the case of this antibody, the light chain is known to have little contribution to antigen binding (Mulleret al, 1998, supra).
- the peptide ligand domain could function to introduce IgG-binding whether introduced at the N-terminus, C-terminus, or inserted within the original Fab sequence. Described here are N-terminal fusions DCAWHLGELVWCTGGG-(light chain) (SEQ ED NO: 112) as well as C-terminal fusions (light chain)-GGGWEADCAWHLGELVWCT (SEQ ID NO: 113).
- HL-569 An oligodeoxynucleotide, HL-569, was designed and synthesized for mutation of anti- VEGF plasmids to create fusions of the IgG-Fc peptide ligand at the N-terminus of the antibody light chain.
- the sequence of HL-569 (with added peptide sequence underlined) is: 5'-ACA AAC GCG TAC GCT GAC TGC GCT TGG CAC CTG GGC GAG CTG GTC TGG TGC ACC GGA GGA GGA GAT ATC CAG TTG ACC-3' (SEQ ID NO: 114).
- the GAC codon follows the STII secretion-signal sequence at the N-terminus of the light chain, and the GAT codon corresponds to the first residue ofthe mature (wild-type) light chain.
- HL-570 Another oligodeoxynucleotide, HL-570, was designed and synthesized for construction of peptide ligand fusions to the C-terminus of the antibody light chain.
- the sequence of HL-570 (with added peptide sequence underlined) is: 5'-AAC AGG GGA GAG TGT GGA GGA GGA TGG GAA GCA GAC TGC GCT TGG CAC CTG GGC GAG CTG GTC TGG TGC ACC TAA GCT GAT CCT CTA C-3' (SEQ ID NO: 115).
- the TGT codon preceding the underscored GGA codon corresponds to residue Cys-214 ofthe light chain, and the TAA "stop codon" marks the end ofthe translated peptide sequence.
- Phagemids pY0192 and pY0317 (described Mulleret al, 1998, supra; Chen et al, 1999; and International Patent Publication No. WO 98/45331, encoding low- affinity and high-affinity forms of a humanized anti-VEGF antibody, respectively, were mutated with each of the two IgG-peptide oligos to yield constructs pYO 192-569, pYO 192-570, pY0317-569, and pY0317-570.
- Displacement curves showed IC50 values of about 100-300 nM for each of the constructs, pY0192-569, pY0192-570, pY0317-569, and pY0317-570.
- EXAMPLE 4 BIAcoreTM Analysis of IgG Binding to Anti-VEGF Fab Tagged with an IgG-Fc Peptide Ligand
- a surface plasmon resonance instrument (BIAcore, Inc., Piscataway, NJ.) was used to measure binding of an irrelevant IgG, 4D5-IgG, also known as Herceptin®, to Fab that previously had been bound to an immobilized VEGF biosensor chip.
- Fab variants encoded by pY0317 and pY0317-570 were expressed in E. coli and purified by protein-G (Pharmacia) affinity chromatography. Recombinant human VEGF was immobilized onto BIAcoreTM CM-5 biosensor chips (BIAcore, Inc.) as described (Muller et al, 1998, supra).
- the chip was blocked with ethanolamine, and the peptide-ligand tagged Y0317-570 Fab, or Y0317 control, was injected in PBS buffer containing 0.05% Tween-20 and 0.01% sodium azide. Following Fab injection, Herceptin® was injected, and the dissociation off-rate (k 0 ff) following injection was observed.
- Fig. 2 show that Herceptin® bound to the tagged but not to the control Y0317 Fab.
- a k 0 ff of 2.8 x 10 ⁇ 3, sec -1 , and a corresponding dissociation half-life (t ⁇ /2) of 8.5 min were calculated for Y0317-570. Limitations of material prevented reliable on-rate determinations.
- the blood clearance rates and tissue distribution of the IgG-Fc peptide ligand-tagged anti- VEGF Fab are compared to those of the untagged control anti-VEGF Fab
- test article present in the plasma samples is determined using any method known in the art, such as, e.g., ELISA, or RIA.
- Pharmacokinetic analysis is performed using the test article plasma concentrations.
- Group mean plasma data for each test article conforms to a multi-exponential profile when plotted against the time post-dosing.
- the data are fit by a standard two-compartment model with bolus input and first-order rate constants for distribution and elimination phases.
- the ⁇ -phase is the initial phase of the clearance and reflects distribution of the protein into all extracellular fluid of the animal, whereas the second or ⁇ -phase portion of the decay curve represents true plasma clearance.
- Serial blood samples (0.5 mL) were collected just prior to dosing and at 10, 20 40 min, 1, 2, 3, 4, 6, 8, 24 and 48 hr after dose administration. Blood was collected in serum separator tubes, allowed to clot ( ⁇ 30 min) at room temperature, and centrifuged. Serum was harvested and immediately stored at -70C until analyzed.
- ELISA plates were coated with 0.5 microg/ml VEGF in 50 mM carbonate buffer, pH 9.6, at 4"C overnight and blocked with 0.5% bovine serum albumin, 10 ppm Proclin 300 (Supelco,
- Bound antibody was detected using peroxidase labeled goat F(ab')2 anti-human IgG F(ab')2 (Jackson ImmunoResearch, West Grove, PA), followed by 3,3',5,5'-tetramethyl benzidine (Kirkegaard & Perry Laboratories) as the substrate. Plates were washed between steps. Absorbance was read at 450 nm on a Titerek stacker reader (ICN, Costa Mesa, CA). The standard curve was fitted using a four-parameter regression curve- fitting program (Kaleidagraph, Synergy Software, Reading, PA). Data points which fell in the range ofthe standard curve were used for calculating the Fab concentrations in samples.
- the initial volume of distribution (VI) for both agents was approximately equal to serum volume.
- the estimated steady state volume, of distribution (Vss) for Fab-Y0317-570 (225 mL/kg) was approximately 2 fold higher than estimated for the control Fab (112 mL/kg) suggesting a significant amount of binding to endogenous IgG.
- the overall exposure (AUC) of Fab-Y0317-570 was -16 times higher than for Fab-Y0317.
- Fab-Y0317 was undetectable in the serum 24 h after dosing but serum concentrations of Fab- Y0317-570 were still above 1 ⁇ g/mL 48 h after dosing. Both the distribution (alpha) half- life (1.15 h) and the elimination (beta) half-life (37.6 h) were significantly longer than the control Fab. These results suggest that addition of a 13 amino acid that binds to endogenous IgG to
- Fab-Y0317 can significantly slow Fab clearance, increase half-life and enhance overall exposure.
- Phage-displayed peptide libraries were selected against rabbit, rat and human albumin. Phage libraries expressing random peptide sequences fused to gene 8 (Lowman et al., Biochem.
- Each ofthe 10 libraries has in excess of 108 clones.
- the phage library pools were suspended in binding buffer (PBS, 1% ovalbumin, 0.005% Tween 20) and sorted against rabbit, rat or human albumin immobilized directly on maxiso ⁇ plates (10 ⁇ g/ml in PBS, overnight at 4° C; plates were blocked with Blocker Casein (Pierce Chemical, Rockford, IL)). After 2 hours, unbound phage were removed by repetitive washing (PBS, 0.05% Tween 20) and bound phage were eluted with 500 mM KC1, 10 mM HCl, pH 2. Eluted phage were propagated in XLl-Blue cells with VCSM13 helper phage (Stratagene, La Jolla, CA). Enrichment was monitored by titering the number of phage that bound to an albumin coated well compared to a well coated with ovalbumin or casein.
- Phage ELISA Phage clones (-10 phage) were added to plates coated with rat, rabbit or human albumin. The microtiter plate was washed with wash buffer and bound phage were detected with HRP/Anti-M13 Conjugate. The amount of HRP bound was measured using ABTS/H 2 0 2 substrate and monitoring the change at 405 nm.
- phage clones selected for binding to rabbit, human or rat albumin are shown in Figure 4. Also indicated is the ability of individual phage clones to bind the 3 species of immobilized albumin. This was tested using a phage ELISA. Note that clone RB, selected for binding to rat albumin is also capable of binding human and rabbit albumin. Sequence Maturation on Monovalent Phage — Partially randomized libraries were designed using oligonucleotides coding for each of the selected clones in Figure 4, but synthesized with a 70-10-10-10 mixture of bases as described (Dennis et al., Nature 404, 465 (2000)).
- each 'soft randomized' library maintains a bias towards the selected sequence in Figure 4.
- Each library was again selected for binding to rat, rabbit or human albumin regardless of its origin.
- the library resulting from soft randomization of clone RB was selected against rat, rabbit or human albumin even though it was originally identified for binding to rat albumin.
- Sequences identified following soft randomization are shown in Figure 5 along with their species specificity as determined by phage ELISA. Most clones appear to be specific for the species of albumin for which they were selected, however, clones from the RB soft randomization library bind to all three species.
- Phage clones were also tested for binding to rhesus, mouse and bovine albumin. Clones originating from the RB soft randomization library were found to bind each of these species of albumin as, well and were specific for albumin based upon their lack of binding to ovalbumin and casein ( Figure 6). Clones that bind to multiple species of albumin (multi-species binders) are listed in Figure 7.
- Hard randomization Sequences from soft randomization ofthe RB sequence were further matured using a hard randomization strategy. A new library was designed that kept highly selected residues (underlined) constant X5DXCLPXWGCLWX4, while fully randomizing the remaining positions. A second library, one residue shorter at both the N and C terminus was also constructed. Sequences from these libraries selected against rat, rabbit and human albumin are shown in Figures 8A, 8B, and 8C respectively.
- Peptide Synthesis Peptides were synthesized by either manual or automated (Milligen 9050) Fmoc-based solid (phase synthesis on a 0.25 mmol scale using a PEG-polystyrene resin (Bodanszky M., (1984) Principles of Peptide Synthesis, Springer, Berlin). Side chain protecting groups were removed and the peptides were cleaved from the resin with 95% trifluoroacetic acid (TFA) and 5% triisopropylsilane. A saturated iodine solution in acetic acid was added for oxidation of disulfide bonds. Peptides were purified by reversed phase HPLC using a water/acetonitrile gradient containing 0.1% TFA. Peptides were >95% pure by analytical HPLC and its identity verified by mass spectrometry.
- the carboxy terminal lysine of peptide SA08 was derivatized with NHS-LC-biotin (Pierce Chemical, Rockford, IL) and purified by HPLC as above yielding SA08b ( Ac-
- the microtiter plate was washed with PBS, 0.05 % Tween 20 and the SA08b bound to albumin was detected with Streptavidin/HRP.
- the amount of HRP bound was measured using ABTS/H2O2 substrate and monitoring the change at 405 ⁇ m.
- Peptides corresponding to identified phage sequences were synthesized and their affinity for rat, rabbit or mouse albumin measured using the SA08b binding assay ( Figure 9 and 10).
- the fusions were expressed under control of the alkaline phosphatase promoter and secreted from E. coli using the stll secretion signal.
- Fab fusions were recovered from theperiplasm by suspending cells in 1 mM EDTA, 10 mM Tris-HCl, pH8, for 1 hr at 4°C. Cell debris was removed by centrifugation and the anti-TF Fab was selectively purified using a Hi-Trap (Amersham Pharmacia Biotech, Piscataway, NJ) TF affinity column.
- D3H44-L or D3H44-Ls was further purified using a rabbit albumin affinity column (rabbit albumin coupled to CNBr-activated Sepharose 4B, Amersham Pharmacia Biotech, Piscataway, NJ). Both columns were washed with PBS and eluted with 50 mM HCl. Eluted fractions were neutralized with 1 M Tris pH 8. Endotoxin was further removed following extraction with triton XI 14 (Aida andPabst, J. Immunol. Methods 132, 191 (1990)).
- D3H44 albumin-binding fusions were given as a 0.5 mg/kg bolus in rabbit. Each group consisted of 3 rabbits (5 in the F(ab')2 group). Serum samples taken at the indicated time points were serially diluted and the concentration of D3H44 determined using a TF binding ELISA.
- Pharmacokinetic analysis is performed using the test article plasma concentrations.
- Group mean plasma data for each test article conforms to a multi-exponential profile when plotted against the time post-dosing.
- the data are fit by a standard two-compartment model with bolus input and first-order rate constants for distribution and elimination phases.
- the ⁇ -phase is the initial phase of the clearance and reflects distribution of the protein into all extracellular fluid of the animal, whereas the second or ⁇ -phase portion of the decay curve represents true plasma clearance.
- D3H44-L has a 70-fold increase in half-life (K10- HL) relative to wild-type Fab and a comparable half-life to D3H44 Fabs derivatized with 20K or 40K polyethylene glycol (PEG).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Processing Of Solid Wastes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU24587/01A AU784285B2 (en) | 1999-12-24 | 2000-12-22 | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US10/149,835 US7608681B2 (en) | 1999-12-24 | 2000-12-22 | Methods and compositions for prolonging elimination half-times of bioactive compounds |
DE60030323T DE60030323T2 (en) | 1999-12-24 | 2000-12-22 | METHOD AND CONNECTIONS FOR EXTENDING THE HALF-TIME PERIODS FOR THE DISPOSAL OF BIOWIRESAMIC COMPOUNDS |
DK00988373T DK1240337T3 (en) | 1999-12-24 | 2000-12-22 | Methods and compositions for prolonging elimination half-lives of bioactive compounds |
JP2001546685A JP2003518075A (en) | 1999-12-24 | 2000-12-22 | Methods and compositions for extending the elimination half-life of bioactive compounds |
CA2390691A CA2390691C (en) | 1999-12-24 | 2000-12-22 | Methods and compositions for prolonging elimination half-times of bioactive compounds |
EP00988373A EP1240337B1 (en) | 1999-12-24 | 2000-12-22 | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US11/367,100 US20060228364A1 (en) | 1999-12-24 | 2006-03-02 | Serum albumin binding peptides for tumor targeting |
AU2006202341A AU2006202341B2 (en) | 1999-12-24 | 2006-06-01 | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US11/535,202 US7635749B2 (en) | 1999-12-24 | 2006-09-26 | Methods and compositions for prolonging elimination half-times of bioactive compounds |
CY20061101596T CY1106236T1 (en) | 1999-12-24 | 2006-11-07 | METHODS AND COMPOSITIONS FOR EXTENSION OF BIOACTIVE COMPOUNDS DISCHARGE HALF-LIVES |
AU2009201933A AU2009201933B2 (en) | 1999-12-24 | 2009-05-15 | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US12/606,055 US20100121039A1 (en) | 1999-12-24 | 2009-10-26 | Methods and compositions for prolonging elimination half-times of bioactive compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17304899P | 1999-12-24 | 1999-12-24 | |
US60/173,048 | 1999-12-24 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10149835 A-371-Of-International | 2000-12-22 | ||
US11/367,100 Continuation-In-Part US20060228364A1 (en) | 1999-12-24 | 2006-03-02 | Serum albumin binding peptides for tumor targeting |
US11/535,202 Continuation US7635749B2 (en) | 1999-12-24 | 2006-09-26 | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US12/606,055 Division US20100121039A1 (en) | 1999-12-24 | 2009-10-26 | Methods and compositions for prolonging elimination half-times of bioactive compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001045746A2 true WO2001045746A2 (en) | 2001-06-28 |
WO2001045746A3 WO2001045746A3 (en) | 2001-10-11 |
Family
ID=22630310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/035325 WO2001045746A2 (en) | 1999-12-24 | 2000-12-22 | Methods and compositions for prolonging elimination half-times of bioactive compounds |
Country Status (12)
Country | Link |
---|---|
US (3) | US7608681B2 (en) |
EP (2) | EP2180054A1 (en) |
JP (3) | JP2003518075A (en) |
AT (2) | ATE337403T1 (en) |
AU (3) | AU784285B2 (en) |
CA (2) | CA2390691C (en) |
CY (1) | CY1106236T1 (en) |
DE (2) | DE60041564D1 (en) |
DK (1) | DK1240337T3 (en) |
ES (1) | ES2270893T3 (en) |
PT (1) | PT1240337E (en) |
WO (1) | WO2001045746A2 (en) |
Cited By (223)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002038592A2 (en) * | 2000-11-08 | 2002-05-16 | Affina Immuntechnik Gmbh | Peptides, the production and use thereof for binding immunoglobulins |
WO2003091395A2 (en) * | 2002-04-24 | 2003-11-06 | Zolaris Biosciences, Llc | Inhibition of immune complex formation |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
US6818611B1 (en) | 1998-10-13 | 2004-11-16 | University Of Georgia Research Foundation, Inc. | Stabilized bioactive peptides and methods of identification, synthesis and use |
EP1532173A1 (en) * | 2002-06-14 | 2005-05-25 | Dyax Corporation | Protein analysis |
WO2005097202A2 (en) * | 2004-04-06 | 2005-10-20 | Affibody Ab | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
EP1587843A2 (en) * | 2002-11-06 | 2005-10-26 | Avidia Research Institute | Combinatorial libraries of monomer domains |
EP1600459A3 (en) * | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
WO2005118642A2 (en) * | 2004-06-01 | 2005-12-15 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
WO2006056492A1 (en) | 2004-11-29 | 2006-06-01 | Bioxell Spa | Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis |
WO2006059106A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
WO2006059108A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
WO2006060533A2 (en) | 2004-12-01 | 2006-06-08 | Genentech, Inc. | Conjugates of 1, 8-bis-naphthalimides with an antibody |
WO2006059110A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
EP1693384A3 (en) * | 2001-10-24 | 2006-11-08 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Functional immunoglobulins against human serum albumin, fragments thereof, library thereof and methods of production thereof |
WO2006122787A1 (en) * | 2005-05-18 | 2006-11-23 | Ablynx Nv | Serum albumin binding proteins |
WO2007030475A1 (en) | 2005-09-06 | 2007-03-15 | Trinity Therapeutics, Inc. | Methods for treating immune mediated neurological diseases |
US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
US7365162B2 (en) | 1998-10-13 | 2008-04-29 | University Of Georgia Research Foundation, Inc. | Stabilized bioactive peptides and methods of identification, synthesis, and use |
WO2008071685A1 (en) * | 2006-12-13 | 2008-06-19 | Ablynx N.V. | Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex |
US7476724B2 (en) | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
WO2009016043A2 (en) | 2007-07-31 | 2009-02-05 | Affibody Ab | New albumin binding compositions, methods and uses |
EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
JP2009511545A (en) * | 2005-10-14 | 2009-03-19 | ノボ・ノルデイスク・エー/エス | Treatment of diabetes using IL-1 inhibitors |
WO2009099719A2 (en) * | 2008-01-31 | 2009-08-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20090258012A1 (en) * | 2001-06-28 | 2009-10-15 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US7608681B2 (en) | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US7714104B2 (en) | 2004-03-10 | 2010-05-11 | Trinity Therapeutics, Inc. | Methods for inhibiting immune complex formation in a subject |
WO2010054699A1 (en) * | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
WO2010111367A1 (en) | 2009-03-25 | 2010-09-30 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
WO2010120561A1 (en) | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
EP2275448A2 (en) | 2003-12-19 | 2011-01-19 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
EP2286844A2 (en) | 2004-06-01 | 2011-02-23 | Genentech, Inc. | Antibody-drug conjugates and methods |
WO2011022264A1 (en) | 2009-08-15 | 2011-02-24 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
WO2011031870A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
WO2011036460A1 (en) | 2009-09-25 | 2011-03-31 | Ucb Pharma S.A. | Disulfide stabilised multivalent antibodies |
WO2011050188A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Anti-hepsin antibodies and methods using same |
WO2011056983A1 (en) | 2009-11-05 | 2011-05-12 | Genentech, Inc. | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
WO2011057120A1 (en) | 2009-11-05 | 2011-05-12 | Genentech, Inc. | Methods and composition for secretion of heterologous polypeptides |
WO2011064382A1 (en) | 2009-11-30 | 2011-06-03 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
WO2011071957A1 (en) | 2009-12-07 | 2011-06-16 | Sea Lane Biotechnologies, Llc | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
WO2011073180A1 (en) | 2009-12-14 | 2011-06-23 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
WO2011098520A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Agonist dr5 binding polypeptides |
WO2011106300A2 (en) | 2010-02-23 | 2011-09-01 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of ovarian cancer |
WO2011117423A1 (en) | 2010-03-26 | 2011-09-29 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2011144749A1 (en) | 2010-05-20 | 2011-11-24 | Ablynx Nv | Biological materials related to her3 |
WO2011153346A1 (en) | 2010-06-03 | 2011-12-08 | Genentech, Inc. | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
WO2011156328A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US8088378B2 (en) | 2007-07-16 | 2012-01-03 | Genetech Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
WO2012004384A2 (en) | 2010-07-09 | 2012-01-12 | Affibody Ab | Polypeptides |
WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
EP2447282A2 (en) | 2006-05-30 | 2012-05-02 | Genentech, Inc. | Anti-CD22 Antibodies, their Immunoconjugates and uses thereof |
WO2012062713A1 (en) | 2010-11-08 | 2012-05-18 | Novartis Ag | Cxcr2 binding polypeptides |
WO2012069654A1 (en) | 2010-11-26 | 2012-05-31 | Molecular Partners Ag | Designed repeat proteins binding to serum albumin |
WO2012074757A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
EP2468776A2 (en) | 2007-02-09 | 2012-06-27 | Genentech, Inc. | Anti-Robo4 antibodies and uses therefor |
WO2012109624A2 (en) | 2011-02-11 | 2012-08-16 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
WO2012130874A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
WO2012155019A1 (en) | 2011-05-12 | 2012-11-15 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
WO2012156219A1 (en) | 2011-05-05 | 2012-11-22 | Ablynx Nv | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
WO2012163887A1 (en) | 2011-05-27 | 2012-12-06 | Ablynx Nv | Inhibition of bone resorption with rankl binding peptides |
EP2535351A2 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
WO2012175740A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Immunoglobulin single variable domains directed against ige |
WO2013004607A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
WO2013007563A1 (en) | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Fusion proteins releasing relaxin and uses thereof |
EP2557090A2 (en) | 2006-12-19 | 2013-02-13 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
WO2013027796A1 (en) | 2011-08-24 | 2013-02-28 | 大塚化学株式会社 | IgG-BINDING PEPTIDE AND METHOD FOR DETECTING AND PURIFYING IgG USING SAME |
WO2013043071A1 (en) | 2011-09-23 | 2013-03-28 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Modified albumin-binding domains and uses thereof to improve pharmacokinetics |
WO2013043070A2 (en) | 2011-09-23 | 2013-03-28 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Anti-tumor necrosis factor-alpha agents and uses thereof |
WO2013045707A2 (en) | 2011-09-30 | 2013-04-04 | Ablynx Nv | Biological materials related to c-met |
WO2013068571A1 (en) | 2011-11-11 | 2013-05-16 | Ucb Pharma S.A. | Albumin binding antibodies and binding fragments thereof |
US8486890B2 (en) | 2006-03-15 | 2013-07-16 | Novo Nordisk A/S | Amylin derivatives |
WO2013112467A1 (en) | 2012-01-23 | 2013-08-01 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
WO2013128027A1 (en) | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
EP2641618A2 (en) | 2007-07-16 | 2013-09-25 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
WO2013143890A1 (en) | 2012-03-28 | 2013-10-03 | Affibody Ab | Oral administration |
EP2650311A2 (en) | 2007-11-27 | 2013-10-16 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
EP2657253A2 (en) | 2008-01-31 | 2013-10-30 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
WO2013168108A2 (en) | 2012-05-09 | 2013-11-14 | Novartis Ag | Chemokine receptor binding polypeptides |
WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
WO2014057073A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
US8703131B2 (en) | 2005-05-21 | 2014-04-22 | Ablynx N.V. | Nanobodies against tumor necrosis factor-alpha |
WO2014064237A1 (en) | 2012-10-25 | 2014-05-01 | Affibody Ab | Abd binding polypeptide |
US8754031B2 (en) | 2004-03-08 | 2014-06-17 | Oncolix, Inc. | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway |
EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
EP2752189A1 (en) | 2008-11-22 | 2014-07-09 | F. Hoffmann-La Roche AG | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
WO2014115229A1 (en) | 2013-01-28 | 2014-07-31 | 独立行政法人産業技術総合研究所 | Antibody-binding peptide |
US8815813B2 (en) | 2008-07-18 | 2014-08-26 | Trinity Therapeutics, Inc. | Methods for treating immune-mediated Dengue Fever infections and antibody-dependent enhancement of Dengue Fever infections, including Dengue Hemorrhagic Fever and Dengue Shock Syndrome |
WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014140358A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Research (Munich) Gmbh | Single chain binding molecules comprising n-terminal abp |
WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
US8895504B2 (en) | 2008-10-21 | 2014-11-25 | Novo Nordisk A/S | Amylin derivatives |
WO2015023355A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
EP2845866A1 (en) | 2006-10-27 | 2015-03-11 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
WO2015095212A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
WO2015095227A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
WO2015095223A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
US9085630B2 (en) | 2002-11-15 | 2015-07-21 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
WO2015139046A1 (en) | 2014-03-14 | 2015-09-17 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
EP2940128A1 (en) * | 2014-04-30 | 2015-11-04 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Adenovirus comprising an albumin-binding moiety |
EP2947097A1 (en) | 2008-04-07 | 2015-11-25 | Ablynx N.V. | Amino acid sequences directed against the Notch pathways and uses thereof |
US9212226B2 (en) | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
EP2621538B1 (en) | 2010-09-28 | 2015-12-16 | Amylin Pharmaceuticals, LLC | Engineered polypeptides having enhanced duration of action |
WO2015193452A1 (en) | 2014-06-18 | 2015-12-23 | Ablynx Nv | Kv1.3 binding immunoglobulins |
WO2015132248A3 (en) * | 2014-03-03 | 2016-01-14 | Vrije Universiteit Brussel (Vub) | Sequamers - a non-natural type of peptide libraries randomly constrained by their primary sequences |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
WO2016040856A2 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
WO2016090050A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
US9371381B2 (en) | 2002-11-08 | 2016-06-21 | Ablynx, N.V. | Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor |
WO2016100803A2 (en) | 2014-12-19 | 2016-06-23 | Alexion Pharmaceuticals, Inc. | Methods of treating tissue calcification |
US20160185874A1 (en) * | 2002-06-28 | 2016-06-30 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US9393304B2 (en) | 2008-10-29 | 2016-07-19 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
WO2016156570A1 (en) | 2015-04-02 | 2016-10-06 | Ablynx N.V. | Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity |
WO2016164308A1 (en) | 2015-04-06 | 2016-10-13 | Subdomain, Llc | De novo binding domain containing polypeptides and uses thereof |
EP3088004A1 (en) | 2004-09-23 | 2016-11-02 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US9487589B2 (en) | 2011-06-30 | 2016-11-08 | Genentech, Inc. | Anti-c-met-antibody formulations |
WO2016180969A1 (en) | 2015-05-13 | 2016-11-17 | Ablynx N.V. | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
WO2016180982A1 (en) | 2015-05-13 | 2016-11-17 | Ablynx N.V. | T cell recruiting polypeptides based on cd3 reactivity |
EP3095455A1 (en) | 2006-12-19 | 2016-11-23 | Genentech, Inc. | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
EP3205670A1 (en) | 2009-06-05 | 2017-08-16 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
US9745340B2 (en) | 2012-10-25 | 2017-08-29 | Affibody Ab | Method for the separation of proteins containing an albumin-binding |
WO2017151707A1 (en) | 2016-03-01 | 2017-09-08 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability |
WO2017165734A1 (en) | 2016-03-25 | 2017-09-28 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
EP3235820A1 (en) | 2014-09-17 | 2017-10-25 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
WO2017218786A1 (en) | 2016-06-16 | 2017-12-21 | Alexion Pharmaceuticals, Inc. | Methods of treating myointimal proliferation |
WO2018007442A1 (en) | 2016-07-06 | 2018-01-11 | Ablynx N.V. | Treatment of il-6r related diseases |
US9884124B2 (en) | 2012-05-17 | 2018-02-06 | Extend Biosciences, Inc. | Carriers for improved drug delivery |
WO2018029182A1 (en) | 2016-08-08 | 2018-02-15 | Ablynx N.V. | Il-6r single variable domain antibodies for treatment of il-6r related diseases |
US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
WO2018050833A1 (en) | 2016-09-15 | 2018-03-22 | Ablynx Nv | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
US9931415B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
EP3311837A1 (en) | 2011-09-23 | 2018-04-25 | Ablynx NV | Prolonged inhibition of interleukin-6 mediated signaling |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
WO2018091606A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10029018B2 (en) | 2013-10-11 | 2018-07-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2018199337A1 (en) | 2017-04-28 | 2018-11-01 | 味の素株式会社 | Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof |
US10118962B2 (en) | 2008-10-29 | 2018-11-06 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
WO2018220235A1 (en) | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Mmp13 binding immunoglobulins |
WO2018220225A1 (en) | 2017-06-02 | 2018-12-06 | Ablynx Nv | Aggrecan binding immunoglobulins |
WO2018220236A1 (en) | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Polypeptides binding adamts5, mmp13 and aggrecan |
WO2018220234A1 (en) | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Adamts binding immunoglobulins |
US10155792B2 (en) | 2012-09-25 | 2018-12-18 | Affibody Ab | Albumin binding polypeptide |
US10167322B2 (en) | 2013-12-20 | 2019-01-01 | Affibody Ab | Engineered albumin binding polypeptide |
EP3424526A1 (en) | 2008-06-05 | 2019-01-09 | Ablynx NV | Immunoglobulin single variable domains binding to the g envelope protein of rabies virus and uses thereof for the treatment and prevention of rabies |
WO2019014360A1 (en) | 2017-07-11 | 2019-01-17 | Alexion Pharmaceuticals, Inc. | Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof |
WO2019032952A1 (en) | 2017-08-11 | 2019-02-14 | The Board Of Trustees Of The University Of Illinois | Truncated guinea pig l-asparaginase variants and methods of use |
US10208120B2 (en) | 2014-11-05 | 2019-02-19 | Genentech, Inc. | Anti-FGFR2/3 antibodies and methods using same |
US10240207B2 (en) | 2014-03-24 | 2019-03-26 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with HGF expression |
EP3461844A2 (en) | 2009-04-10 | 2019-04-03 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
WO2019067502A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) |
EP3470425A2 (en) | 2008-12-19 | 2019-04-17 | Ablynx N.V. | Immunoglobulins against cell-associatd antigens such as p2x7 |
WO2019072868A1 (en) | 2017-10-10 | 2019-04-18 | Numab Therapeutics AG | Multispecific antibody |
CN109790202A (en) * | 2016-09-30 | 2019-05-21 | 富士胶片株式会社 | Cyclic peptide, affinity chromatography carrier, labelled antibody, antibody drug complex and pharmaceutical preparation |
WO2019099440A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Multifunctional immune cell therapies |
US10392393B2 (en) | 2016-01-26 | 2019-08-27 | Medimmune Limited | Pyrrolobenzodiazepines |
US10406202B2 (en) | 2014-10-22 | 2019-09-10 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2019240288A1 (en) | 2018-06-14 | 2019-12-19 | 味の素株式会社 | Substance having affinity for antibody, and compound or salt thereof having bioorthogonal functional group |
US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
US10543279B2 (en) | 2016-04-29 | 2020-01-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer |
JP2020033372A (en) * | 2012-03-28 | 2020-03-05 | アフィボディ・アーベー | Oral administration |
US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
WO2020090979A1 (en) | 2018-10-31 | 2020-05-07 | 味の素株式会社 | Compound comprising substance with affinity for antibody, cleavage site and reactive group, or salt thereof |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10695439B2 (en) | 2016-02-10 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
EP3816185A1 (en) | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
US11000510B2 (en) | 2014-09-23 | 2021-05-11 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
US11008365B2 (en) | 2016-09-01 | 2021-05-18 | National Institute Of Advanced Industrial Science And Technology | Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure |
WO2021123186A1 (en) | 2019-12-20 | 2021-06-24 | UCB Biopharma SRL | Multi-specific antibody with binding specificity for human il-13 and il-17 |
US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
US11124573B2 (en) | 2014-05-02 | 2021-09-21 | Janssen Biotech, Inc. | Compositions and methods related to engineered Fc constructs |
US11135303B2 (en) | 2011-10-14 | 2021-10-05 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11155640B2 (en) | 2016-05-23 | 2021-10-26 | Janssen Biotech, Inc. | Compositions and methods related to engineered Fc constructs |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
EP3915580A1 (en) | 2020-05-29 | 2021-12-01 | Numab Therapeutics AG | Multispecific antibody |
US11208452B2 (en) | 2015-06-02 | 2021-12-28 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
EP3932945A1 (en) | 2015-11-27 | 2022-01-05 | Ablynx NV | Polypeptides inhibiting cd40l |
WO2022004805A1 (en) | 2020-06-30 | 2022-01-06 | 株式会社ガイアバイオメディシン | Method for stabilizing binding of antibody to nk cell and use thereof |
US11220531B2 (en) | 2017-01-06 | 2022-01-11 | Janssen Biotech, Inc. | Engineered Fc constructs |
US11292825B2 (en) | 2015-10-01 | 2022-04-05 | Novo Nordisk A/S | Protein conjugates |
EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
WO2022098745A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
WO2022122654A1 (en) | 2020-12-07 | 2022-06-16 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2022167460A1 (en) | 2021-02-02 | 2022-08-11 | Numab Therapeutics AG | Multispecific antibodies having specificity for ror1 and cd3 |
WO2022178255A2 (en) | 2021-02-19 | 2022-08-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies that neutralize sars-cov-2 |
US11471537B2 (en) | 2017-04-05 | 2022-10-18 | Novo Nordisk A/S | Oligomer extended insulin-Fc conjugates |
US11517626B2 (en) | 2016-02-10 | 2022-12-06 | Medimmune Limited | Pyrrolobenzodiazepine antibody conjugates |
US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11642416B2 (en) | 2017-08-09 | 2023-05-09 | Massachusetts Institute Of Technology | Albumin binding peptide conjugates and methods thereof |
US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
EP4183800A1 (en) | 2021-11-19 | 2023-05-24 | Medizinische Hochschule Hannover | Novel sars-cov-2 neutralizing antibodies |
US11702473B2 (en) | 2015-04-15 | 2023-07-18 | Medimmune Limited | Site-specific antibody-drug conjugates |
WO2024008904A2 (en) | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
WO2024038095A1 (en) | 2022-08-16 | 2024-02-22 | Iome Bio | NOVEL ANTI-RGMb ANTIBODIES |
WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
DE10012120A1 (en) * | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | New ligand, comprising therapeutic or diagnostic agent bonded non-covalently with substance having high affinity to transport molecule |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US7329725B1 (en) * | 2003-10-29 | 2008-02-12 | Nastech Pharmaceutical Company Inc. | Phage displayed Trp cage ligands |
AU2011253771B2 (en) * | 2004-03-10 | 2013-10-31 | Trinity Therapeutics, Inc. | Method for inhibiting immune complex formation in a subject |
WO2007094842A2 (en) | 2005-12-02 | 2007-08-23 | Genentech, Inc. | Binding polypeptides and uses thereof |
US7704953B2 (en) * | 2006-02-17 | 2010-04-27 | Mdrna, Inc. | Phage displayed cell binding peptides |
JP2010505435A (en) * | 2006-10-11 | 2010-02-25 | アブリンクス エン.ヴェー. | Amino acid sequences that bind to serum proteins essentially independently of pH, compounds containing them, and uses thereof |
KR100920729B1 (en) * | 2007-10-01 | 2009-10-07 | 한국생명공학연구원 | Method for preparing antibody monolayers which have controlled orientation using peptide hybrid |
EP2304033B1 (en) | 2008-06-30 | 2016-09-07 | ESBATech, an Alcon Biomedical Research Unit LLC | Functionalized polypeptides |
CN102088958A (en) | 2008-07-10 | 2011-06-08 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | Methods and compositions for enhanced delivery of macromolecules |
US8648046B2 (en) * | 2009-02-26 | 2014-02-11 | Oncolix, Inc. | Compositions and methods for visualizing and eliminating cancer stem cells |
JP5963443B2 (en) | 2009-02-26 | 2016-08-03 | オンコリックス, インコーポレイテッド | Compositions and methods for visualizing and eliminating cancer stem cells |
HUE029454T2 (en) | 2009-11-13 | 2017-03-28 | Grifols Therapeutics Inc | Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto |
US8822423B2 (en) * | 2012-05-17 | 2014-09-02 | Janssen Biotech, Inc. | Affinity peptides toward infliximab |
KR102053674B1 (en) | 2012-05-25 | 2019-12-09 | 얀센 바이오테크 인코포레이티드 | Non-natural consensus albumin binding domains |
WO2013192546A1 (en) * | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
WO2014003176A1 (en) * | 2012-06-29 | 2014-01-03 | 旭化成メディカル株式会社 | Adsorbent comprising carrier bonded with polypeptide comprising b-domain mutant derived from protein a |
AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
CN110627797A (en) | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | Asymmetric pyrrolobenzodiazepine dimers for the treatment of proliferative and autoimmune diseases |
SG11201803001WA (en) * | 2015-10-23 | 2018-05-30 | Fujifilm Corp | Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation |
US10478503B2 (en) | 2016-01-31 | 2019-11-19 | University Of Massachusetts | Branched oligonucleotides |
SG11201808914UA (en) | 2016-04-15 | 2018-11-29 | Berkeley Lights Inc | Methods, systems and kits for in-pen assays |
JP7111627B2 (en) | 2016-06-03 | 2022-08-02 | ヤンセン バイオテツク,インコーポレーテツド | serum albumin binding fibronectin type III domain |
CA3033368A1 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
EP3538560A4 (en) * | 2016-11-10 | 2020-06-17 | Keros Therapeutics, Inc. | Gdnf fusion polypeptides and methods of use thereof |
JP7406793B2 (en) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | Two-tail self-delivery siRNA and related methods |
WO2019075476A2 (en) | 2017-10-15 | 2019-04-18 | Berkeley Lights, Inc. | Methods, systems and kits for in-pen assays |
KR102037336B1 (en) * | 2017-11-29 | 2019-10-29 | 아주대학교산학협력단 | Method to Conjugate Antibody and Physiologically Active Compound |
WO2019107962A2 (en) * | 2017-11-29 | 2019-06-06 | 아주대학교 산학협력단 | Method for conjugating antibody and physiologically active substance |
EP3833763A4 (en) | 2018-08-10 | 2023-07-19 | University of Massachusetts | Modified oligonucleotides targeting snps |
BR112021005907A2 (en) | 2018-09-27 | 2021-08-10 | Xilio Development, Inc. | masked cytokines, nucleic acid, vector, host cell, methods for producing a masked cytokine, for treating or preventing a neoplastic disease and for treating or preventing a neoplastic inflammatory or autoimmune disease, composition, pharmaceutical composition and kit |
EA202191728A1 (en) * | 2018-12-20 | 2021-10-12 | Клео Фармасьютикалс, Инк. | COMBINED THERAPY FOR ARM AND NATURAL KILLER CELLS |
JP2022523467A (en) * | 2019-01-18 | 2022-04-25 | ユニバーシティ・オブ・マサチューセッツ | Anchors that modify dynamic pharmacokinetics |
CN114502730A (en) | 2019-08-09 | 2022-05-13 | 马萨诸塞大学 | Chemically modified SNP-targeting oligonucleotides |
MX2023015523A (en) | 2021-06-23 | 2024-03-11 | Univ Massachusetts | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders. |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991001743A1 (en) * | 1989-08-01 | 1991-02-21 | Cemu Bioteknik Ab | Stabilized protein or peptide conjugates |
EP0602290A1 (en) * | 1992-12-04 | 1994-06-22 | Philippe Pouletty | Cellular drug anchors |
WO1994018318A1 (en) * | 1993-02-01 | 1994-08-18 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
WO1998022141A2 (en) * | 1996-11-19 | 1998-05-28 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US763829A (en) | 1903-01-16 | 1904-06-28 | L E Knott Apparatus Company | Apparatus for reading angular deflections. |
US3561444A (en) | 1968-05-22 | 1971-02-09 | Bio Logics Inc | Ultrasonic drug nebulizer |
US3703173A (en) | 1970-12-31 | 1972-11-21 | Ted A Dixon | Nebulizer and tent assembly |
US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
JPS5726506B2 (en) * | 1974-03-08 | 1982-06-04 | ||
US4105603A (en) * | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4624251A (en) | 1984-09-13 | 1986-11-25 | Riker Laboratories, Inc. | Apparatus for administering a nebulized substance |
US4635627A (en) * | 1984-09-13 | 1987-01-13 | Riker Laboratories, Inc. | Apparatus and method |
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4824659A (en) * | 1985-06-07 | 1989-04-25 | Immunomedics, Inc. | Antibody conjugates |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5079233A (en) * | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
IE81149B1 (en) | 1987-02-12 | 2000-05-03 | Genentech Inc | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
US5223427A (en) | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
WO1989005859A1 (en) | 1987-12-21 | 1989-06-29 | The Upjohn Company | Agrobacterium mediated transformation of germinating plant seeds |
US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
JP3040121B2 (en) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | Methods of treating tumor cells by inhibiting growth factor receptor function |
US5135736A (en) * | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
JP2848411B2 (en) | 1988-08-18 | 1999-01-20 | サイオス インコーポレイテッド | Atrial natriuretic peptide clearance inhibitor |
WO1990003430A1 (en) | 1988-09-23 | 1990-04-05 | Cetus Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
WO1992000748A1 (en) | 1990-07-06 | 1992-01-23 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
CA2101918A1 (en) | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
JP4124480B2 (en) * | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ATE168014T1 (en) * | 1991-11-08 | 1998-07-15 | Somatogen Inc | HEMOGLOBINS AS A DRUG DELIVERY SYSTEM |
US5288931A (en) | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
WO1995009864A1 (en) * | 1993-10-01 | 1995-04-13 | Teikoku Hormone Mfg. Co., Ltd. | Novel peptide derivative |
US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
SE9400088D0 (en) * | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
DK0833911T3 (en) | 1995-06-07 | 2004-08-30 | Ortho Mcneil Pharm Inc | CDR grafted anti-tissue factor antibodies and methods for their use |
US5780054A (en) * | 1996-01-17 | 1998-07-14 | University Of British Columbia | Methods for increasing the circulation half-life of protein-based therapeutics |
US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
EP1787999B1 (en) | 1997-04-07 | 2010-08-04 | Genentech, Inc. | Anti-VEGF antibodies |
US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
EP2180054A1 (en) | 1999-12-24 | 2010-04-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US20060228364A1 (en) * | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US6632979B2 (en) * | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US20030171267A1 (en) | 2000-04-12 | 2003-09-11 | Rosen Craig A. | Albumin fusion proteins |
US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
CA2440582A1 (en) * | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
US20050089932A1 (en) * | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20030009395A1 (en) * | 2001-07-06 | 2003-01-09 | Yu Philip Shi-Lung | Method and apparatus for providing information regarding a product |
ES2561985T3 (en) | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodeling and glycoconjugation of antibodies |
JP2005511627A (en) | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス,インコーポレーテッド | Treatment of immunological diseases using anti-CD30 antibodies |
US7435797B2 (en) * | 2002-04-10 | 2008-10-14 | Genentech, Inc. | Anti-HER2 antibody variants |
JP3997859B2 (en) * | 2002-07-25 | 2007-10-24 | 株式会社日立製作所 | Semiconductor device manufacturing method and manufacturing apparatus |
CA2494104A1 (en) | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
US20040032828A1 (en) * | 2002-08-16 | 2004-02-19 | Cellglide Technologies Corp. | Service management in cellular networks |
-
2000
- 2000-12-22 EP EP09016036A patent/EP2180054A1/en not_active Withdrawn
- 2000-12-22 PT PT00988373T patent/PT1240337E/en unknown
- 2000-12-22 ES ES00988373T patent/ES2270893T3/en not_active Expired - Lifetime
- 2000-12-22 CA CA2390691A patent/CA2390691C/en not_active Expired - Lifetime
- 2000-12-22 DE DE60041564T patent/DE60041564D1/en not_active Expired - Lifetime
- 2000-12-22 AU AU24587/01A patent/AU784285B2/en not_active Expired
- 2000-12-22 AT AT00988373T patent/ATE337403T1/en active
- 2000-12-22 DK DK00988373T patent/DK1240337T3/en active
- 2000-12-22 CA CA2921260A patent/CA2921260A1/en not_active Abandoned
- 2000-12-22 WO PCT/US2000/035325 patent/WO2001045746A2/en active IP Right Grant
- 2000-12-22 EP EP00988373A patent/EP1240337B1/en not_active Expired - Lifetime
- 2000-12-22 US US10/149,835 patent/US7608681B2/en active Active
- 2000-12-22 JP JP2001546685A patent/JP2003518075A/en active Pending
- 2000-12-22 DE DE60030323T patent/DE60030323T2/en not_active Expired - Lifetime
- 2000-12-22 AT AT06017276T patent/ATE422369T1/en not_active IP Right Cessation
-
2006
- 2006-06-01 AU AU2006202341A patent/AU2006202341B2/en not_active Expired
- 2006-09-26 US US11/535,202 patent/US7635749B2/en not_active Expired - Fee Related
- 2006-11-07 CY CY20061101596T patent/CY1106236T1/en unknown
-
2007
- 2007-04-17 JP JP2007107978A patent/JP5004640B2/en not_active Expired - Lifetime
- 2007-06-11 JP JP2007154102A patent/JP4949132B2/en not_active Expired - Lifetime
-
2009
- 2009-05-15 AU AU2009201933A patent/AU2009201933B2/en not_active Expired
- 2009-10-26 US US12/606,055 patent/US20100121039A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991001743A1 (en) * | 1989-08-01 | 1991-02-21 | Cemu Bioteknik Ab | Stabilized protein or peptide conjugates |
EP0602290A1 (en) * | 1992-12-04 | 1994-06-22 | Philippe Pouletty | Cellular drug anchors |
WO1994018318A1 (en) * | 1993-02-01 | 1994-08-18 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
WO1998022141A2 (en) * | 1996-11-19 | 1998-05-28 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
Non-Patent Citations (2)
Title |
---|
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; MAKRIDES S C ET AL: "Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor." retrieved from STN Database accession no. 96185117 XP002169607 & JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1996 APR) 277 (1) 534-42. , cited in the application * |
P YEH ET AL.: "Design of yeast-secreted albumin derivatives for hiuman therapy; biological and antiviral properties of a serum albumin-CD4 genetic conjugate" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 89, 1992, pages 1904-1908, XP002130704 NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US ISSN: 0027-8424 cited in the application * |
Cited By (375)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122516B2 (en) | 1998-10-13 | 2006-10-17 | University Of Georgia Research Foundation, Inc. | Stabilized bioactive peptides and methods of identification, synthesis and use |
US10018618B2 (en) | 1998-10-13 | 2018-07-10 | Peptide Biosciences, Inc. | Stabilizied bioactive peptides and methods of identification, synthesis and use |
US9322829B2 (en) | 1998-10-13 | 2016-04-26 | Peptide Biosciences, Inc. | Stabilized bioactive peptides and methods of identification, synthesis, and use |
US8440201B2 (en) | 1998-10-13 | 2013-05-14 | University Of Georgia Research Foundation, Inc. | Stabilized bioactive peptides and methods of identification, synthesis, and use |
US7365162B2 (en) | 1998-10-13 | 2008-04-29 | University Of Georgia Research Foundation, Inc. | Stabilized bioactive peptides and methods of identification, synthesis, and use |
US6818611B1 (en) | 1998-10-13 | 2004-11-16 | University Of Georgia Research Foundation, Inc. | Stabilized bioactive peptides and methods of identification, synthesis and use |
US8030464B2 (en) | 1998-10-13 | 2011-10-04 | The University Of Georgia Research Foundation, Inc | Stabilized bioactive peptides and methods of identification, synthesis, and use |
US7608681B2 (en) | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US7635749B2 (en) | 1999-12-24 | 2009-12-22 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US7205382B2 (en) | 2000-11-08 | 2007-04-17 | Fresenius Medical Care Affina Gmbh | Peptides, the production and use thereof for binding immunoglobulins |
WO2002038592A3 (en) * | 2000-11-08 | 2003-01-23 | Affina Immuntechnik Gmbh | Peptides, the production and use thereof for binding immunoglobulins |
WO2002038592A2 (en) * | 2000-11-08 | 2002-05-16 | Affina Immuntechnik Gmbh | Peptides, the production and use thereof for binding immunoglobulins |
US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
US20090258012A1 (en) * | 2001-06-28 | 2009-10-15 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US8097251B2 (en) | 2001-10-24 | 2012-01-17 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof |
EP1693384A3 (en) * | 2001-10-24 | 2006-11-08 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Functional immunoglobulins against human serum albumin, fragments thereof, library thereof and methods of production thereof |
US9156905B2 (en) | 2001-10-24 | 2015-10-13 | Vib Vzw | Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof |
US6916904B2 (en) | 2002-04-24 | 2005-07-12 | Zolaris Biosciences, Llc | Inhibition of immune complex formation |
US7584059B2 (en) | 2002-04-24 | 2009-09-01 | Trinity Therapeuties, Inc. | Inhibition of immune complex formation |
WO2003091395A3 (en) * | 2002-04-24 | 2004-10-14 | Zolaris Biosciences Llc | Inhibition of immune complex formation |
WO2003091395A2 (en) * | 2002-04-24 | 2003-11-06 | Zolaris Biosciences, Llc | Inhibition of immune complex formation |
EP1532173A1 (en) * | 2002-06-14 | 2005-05-25 | Dyax Corporation | Protein analysis |
EP1532173A4 (en) * | 2002-06-14 | 2006-03-08 | Dyax Corp | Protein analysis |
US20160185874A1 (en) * | 2002-06-28 | 2016-06-30 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
EP1600459A3 (en) * | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
EP1587843A4 (en) * | 2002-11-06 | 2008-01-09 | Avidia Inc | Combinatorial libraries of monomer domains |
EP1587843A2 (en) * | 2002-11-06 | 2005-10-26 | Avidia Research Institute | Combinatorial libraries of monomer domains |
JP2007524341A (en) * | 2002-11-06 | 2007-08-30 | アビディア インコーポレイテッド | Monomer domain combinatorial library |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
US9243065B2 (en) | 2002-11-08 | 2016-01-26 | Ablynx N.V. | Polypeptide constructs including VHH directed against EGFR for intracellular delivery |
US9371381B2 (en) | 2002-11-08 | 2016-06-21 | Ablynx, N.V. | Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor |
EP2316852A1 (en) | 2002-11-08 | 2011-05-04 | Ablynx N.V. | Stabilized single domain antibodies |
JP2006520584A (en) * | 2002-11-08 | 2006-09-14 | アブリンクス エン.ヴェー. | Stabilized single domain antibody |
US9725522B2 (en) | 2002-11-08 | 2017-08-08 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
EP2336179A1 (en) | 2002-11-08 | 2011-06-22 | Ablynx N.V. | Stabilized single domain antibodies |
US9085630B2 (en) | 2002-11-15 | 2015-07-21 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
EP2275448A2 (en) | 2003-12-19 | 2011-01-19 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
US8754031B2 (en) | 2004-03-08 | 2014-06-17 | Oncolix, Inc. | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway |
US8362202B2 (en) | 2004-03-10 | 2013-01-29 | Trinity Therapeutics, Inc. | Methods for inhibiting immune complex formation in a subject |
US7714104B2 (en) | 2004-03-10 | 2010-05-11 | Trinity Therapeutics, Inc. | Methods for inhibiting immune complex formation in a subject |
US10179803B2 (en) | 2004-03-10 | 2019-01-15 | Trinity Therapeutics, Inc. | Methods for inhibiting immune complex formation in a subject |
US9447145B2 (en) | 2004-03-10 | 2016-09-20 | Trinity Therapeutics, Inc. | Compositions for inhibiting immune complex formation in a subject |
US7786258B2 (en) | 2004-03-10 | 2010-08-31 | Trinity Therapeutics, Inc. | Methods for inhibiting immune complex formation in a subject |
US8642743B2 (en) | 2004-04-06 | 2014-02-04 | Affibody Ab | Method for reducing the immune response to a biologically active protein |
WO2005097202A3 (en) * | 2004-04-06 | 2006-04-27 | Affibody Ab | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
EP2380594A1 (en) | 2004-04-06 | 2011-10-26 | Affibody AB | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
WO2005097202A2 (en) * | 2004-04-06 | 2005-10-20 | Affibody Ab | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
AU2005250216B2 (en) * | 2004-06-01 | 2009-12-10 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
EP2740743A2 (en) | 2004-06-01 | 2014-06-11 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
EP2740743A3 (en) * | 2004-06-01 | 2015-08-19 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
WO2005118642A2 (en) * | 2004-06-01 | 2005-12-15 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
EP2286844A2 (en) | 2004-06-01 | 2011-02-23 | Genentech, Inc. | Antibody-drug conjugates and methods |
EA012622B1 (en) * | 2004-06-01 | 2009-10-30 | Домэнтис Лимитед | Bispecific fusion antibodies with enhanced serum half-life |
WO2005118642A3 (en) * | 2004-06-01 | 2006-03-23 | Domantis Ltd | Bispecific fusion antibodies with enhanced serum half-life |
US7476724B2 (en) | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
EP3088004A1 (en) | 2004-09-23 | 2016-11-02 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2006056492A1 (en) | 2004-11-29 | 2006-06-01 | Bioxell Spa | Therapeutic peptides comprising sequences derived from cdr2 or cdr3 of trem-1 and uses thereof to inhibit sepsis |
US10603357B2 (en) | 2004-11-29 | 2020-03-31 | Bristol-Myers Squibb Company | Therapeutic TREM-1 peptides |
WO2006060533A2 (en) | 2004-12-01 | 2006-06-08 | Genentech, Inc. | Conjugates of 1, 8-bis-naphthalimides with an antibody |
WO2006059106A3 (en) * | 2004-12-02 | 2007-01-04 | Domantis Ltd | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
EP2769990A2 (en) | 2004-12-02 | 2014-08-27 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY |
WO2006059108A3 (en) * | 2004-12-02 | 2007-02-22 | Domantis Ltd | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
WO2006059110A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
WO2006059110A3 (en) * | 2004-12-02 | 2007-03-15 | Domantis Ltd | Plad domain peptides with increased serum half life due to conjugation to domain antibodies |
WO2006059108A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
WO2006059106A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
US11472871B2 (en) | 2005-05-18 | 2022-10-18 | Ablynx N.V. | Nanobodies against tumor necrosis factor-alpha |
EP2365000A2 (en) | 2005-05-18 | 2011-09-14 | Ablynx N.V. | Improved nanobodiesTM against tumor necrosis factor-alpha |
US9067991B2 (en) | 2005-05-18 | 2015-06-30 | Ablynx N.V. | Nanobodies against tumor necrosis factor-alpha |
EP2172484A2 (en) | 2005-05-18 | 2010-04-07 | Ablynx N.V. | Serum albumin binding proteins |
EP2949668A1 (en) | 2005-05-18 | 2015-12-02 | Ablynx N.V. | Improved nanobodiestm against tumor necrosis factor-alpha |
EP2172484A3 (en) * | 2005-05-18 | 2010-05-19 | Ablynx N.V. | Serum albumin binding proteins |
EP2365000A3 (en) * | 2005-05-18 | 2013-01-16 | Ablynx N.V. | Improved nanobodiesTM against tumor necrosis factor-alpha |
US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
NO345340B1 (en) * | 2005-05-18 | 2020-12-21 | Ablynx Nv | Amino acid sequence, fusion protein or construct containing this amino acid sequence, as well as a method for producing the amino acid sequence. |
EP2479191A2 (en) | 2005-05-18 | 2012-07-25 | Ablynx N.V. | Improved nanobodiesTM against tumor necrosis factor-alpha |
EP3613767A1 (en) | 2005-05-18 | 2020-02-26 | Ablynx N.V. | Improved nanobodiestm against tumor cecrosis factor-alpha |
WO2006122787A1 (en) * | 2005-05-18 | 2006-11-23 | Ablynx Nv | Serum albumin binding proteins |
US8703131B2 (en) | 2005-05-21 | 2014-04-22 | Ablynx N.V. | Nanobodies against tumor necrosis factor-alpha |
EP1940436A1 (en) * | 2005-09-06 | 2008-07-09 | Trinity Therapeutics, Inc. | Methods for treating immune mediated neurological diseases |
WO2007030475A1 (en) | 2005-09-06 | 2007-03-15 | Trinity Therapeutics, Inc. | Methods for treating immune mediated neurological diseases |
EP1940436A4 (en) * | 2005-09-06 | 2012-05-30 | Trinity Therapeutics Inc | Methods for treating immune mediated neurological diseases |
JP2009511545A (en) * | 2005-10-14 | 2009-03-19 | ノボ・ノルデイスク・エー/エス | Treatment of diabetes using IL-1 inhibitors |
US8486890B2 (en) | 2006-03-15 | 2013-07-16 | Novo Nordisk A/S | Amylin derivatives |
EP2447282A2 (en) | 2006-05-30 | 2012-05-02 | Genentech, Inc. | Anti-CD22 Antibodies, their Immunoconjugates and uses thereof |
EP2446904A2 (en) | 2006-05-30 | 2012-05-02 | Genentech, Inc. | Anti-CD22 antibodies, their immunoconjugates and uses thereof |
US8968741B2 (en) | 2006-05-30 | 2015-03-03 | Genentech, Inc. | Anti-CD22 antibodies and immunoconjugates and methods of use |
US8394607B2 (en) | 2006-05-30 | 2013-03-12 | Genentech, Inc. | Anti-CD22 antibodies and immunoconjugates and methods of use |
US8524865B2 (en) | 2006-05-30 | 2013-09-03 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
US8226945B2 (en) | 2006-05-30 | 2012-07-24 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
EP2845866A1 (en) | 2006-10-27 | 2015-03-11 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
WO2008071685A1 (en) * | 2006-12-13 | 2008-06-19 | Ablynx N.V. | Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex |
EP3095455A1 (en) | 2006-12-19 | 2016-11-23 | Genentech, Inc. | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
EP2557090A2 (en) | 2006-12-19 | 2013-02-13 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
EP2468776A2 (en) | 2007-02-09 | 2012-06-27 | Genentech, Inc. | Anti-Robo4 antibodies and uses therefor |
US8691531B2 (en) | 2007-07-16 | 2014-04-08 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US8088378B2 (en) | 2007-07-16 | 2012-01-03 | Genetech Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10494432B2 (en) | 2007-07-16 | 2019-12-03 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US11866496B2 (en) | 2007-07-16 | 2024-01-09 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
US8545850B2 (en) | 2007-07-16 | 2013-10-01 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
EP2474557A2 (en) | 2007-07-16 | 2012-07-11 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
EP2641618A2 (en) | 2007-07-16 | 2013-09-25 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
EP2502937A2 (en) | 2007-07-16 | 2012-09-26 | Genentech, Inc. | Anti-CD 79b Antibodies And Immunoconjugates And Methods Of Use |
USRE48558E1 (en) | 2007-07-16 | 2021-05-18 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10981987B2 (en) | 2007-07-16 | 2021-04-20 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
EP2546261A2 (en) | 2007-07-31 | 2013-01-16 | Affibody AB | New compositions, methods and use |
WO2009016043A2 (en) | 2007-07-31 | 2009-02-05 | Affibody Ab | New albumin binding compositions, methods and uses |
EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
WO2009034119A1 (en) * | 2007-09-11 | 2009-03-19 | Novo Nordisk A/S | Improved derivatives of amylin |
EP2535350A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
US10100130B2 (en) | 2007-09-26 | 2018-10-16 | Ucb Biopharma Sprl | Dual specificity antibody fusions |
US9309327B2 (en) | 2007-09-26 | 2016-04-12 | Ucb Pharma S.A. | Dual specificity antibody fusions |
US11427650B2 (en) | 2007-09-26 | 2022-08-30 | UCB Biopharma SRL | Dual specificity antibody fusions |
US8629246B2 (en) | 2007-09-26 | 2014-01-14 | Ucb Pharma S.A. | Dual specificity antibody fusions |
US9828438B2 (en) | 2007-09-26 | 2017-11-28 | Ucb Pharma S.A. | Dual specificity antibody fusions |
EP2535351A2 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
EP2650311A2 (en) | 2007-11-27 | 2013-10-16 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
US9896506B2 (en) | 2008-01-31 | 2018-02-20 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10544218B2 (en) | 2008-01-31 | 2020-01-28 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
WO2009099719A2 (en) * | 2008-01-31 | 2009-08-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
WO2009099719A3 (en) * | 2008-01-31 | 2009-10-29 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
EP2657253A2 (en) | 2008-01-31 | 2013-10-30 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
EP2947097A1 (en) | 2008-04-07 | 2015-11-25 | Ablynx N.V. | Amino acid sequences directed against the Notch pathways and uses thereof |
US9212226B2 (en) | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
EP3424526A1 (en) | 2008-06-05 | 2019-01-09 | Ablynx NV | Immunoglobulin single variable domains binding to the g envelope protein of rabies virus and uses thereof for the treatment and prevention of rabies |
US8815813B2 (en) | 2008-07-18 | 2014-08-26 | Trinity Therapeutics, Inc. | Methods for treating immune-mediated Dengue Fever infections and antibody-dependent enhancement of Dengue Fever infections, including Dengue Hemorrhagic Fever and Dengue Shock Syndrome |
US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
US8895504B2 (en) | 2008-10-21 | 2014-11-25 | Novo Nordisk A/S | Amylin derivatives |
US9993552B2 (en) | 2008-10-29 | 2018-06-12 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
US10118962B2 (en) | 2008-10-29 | 2018-11-06 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
US11370835B2 (en) | 2008-10-29 | 2022-06-28 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
US9393304B2 (en) | 2008-10-29 | 2016-07-19 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
WO2010054699A1 (en) * | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
EP3178478A1 (en) | 2008-11-22 | 2017-06-14 | F. Hoffmann-La Roche AG | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
EP2752189A1 (en) | 2008-11-22 | 2014-07-09 | F. Hoffmann-La Roche AG | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
EP3470425A2 (en) | 2008-12-19 | 2019-04-17 | Ablynx N.V. | Immunoglobulins against cell-associatd antigens such as p2x7 |
WO2010111367A1 (en) | 2009-03-25 | 2010-09-30 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
WO2010120561A1 (en) | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
EP3461844A2 (en) | 2009-04-10 | 2019-04-03 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
EP3205670A1 (en) | 2009-06-05 | 2017-08-16 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
WO2011022264A1 (en) | 2009-08-15 | 2011-02-24 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
EP3090758A1 (en) | 2009-08-15 | 2016-11-09 | F. Hoffmann-La Roche AG | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
WO2011031870A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
WO2011036460A1 (en) | 2009-09-25 | 2011-03-31 | Ucb Pharma S.A. | Disulfide stabilised multivalent antibodies |
WO2011050188A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Anti-hepsin antibodies and methods using same |
WO2011057120A1 (en) | 2009-11-05 | 2011-05-12 | Genentech, Inc. | Methods and composition for secretion of heterologous polypeptides |
WO2011056983A1 (en) | 2009-11-05 | 2011-05-12 | Genentech, Inc. | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
WO2011064382A1 (en) | 2009-11-30 | 2011-06-03 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
EP3778917A2 (en) | 2009-12-04 | 2021-02-17 | F. Hoffmann-La Roche AG | Multispecific antibodies, antibody analogs, compositions, and methods |
US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
WO2011071957A1 (en) | 2009-12-07 | 2011-06-16 | Sea Lane Biotechnologies, Llc | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
WO2011073180A1 (en) | 2009-12-14 | 2011-06-23 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
EP3309176A1 (en) | 2009-12-14 | 2018-04-18 | Ablynx N.V. | Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use |
WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
WO2011098520A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Agonist dr5 binding polypeptides |
EP3696194A1 (en) | 2010-02-23 | 2020-08-19 | F. Hoffmann-La Roche AG | Anti-angiogenesis therapy for the treatment of ovarian cancer |
WO2011106300A2 (en) | 2010-02-23 | 2011-09-01 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of ovarian cancer |
US9758584B2 (en) | 2010-03-26 | 2017-09-12 | Ablynx N.V. | Biological materials related to CXCR7 |
WO2011117423A1 (en) | 2010-03-26 | 2011-09-29 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
US8937164B2 (en) | 2010-03-26 | 2015-01-20 | Ablynx N.V. | Biological materials related to CXCR7 |
WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
EP3546483A1 (en) | 2010-05-20 | 2019-10-02 | Ablynx N.V. | Biological materials related to her3 |
WO2011144749A1 (en) | 2010-05-20 | 2011-11-24 | Ablynx Nv | Biological materials related to her3 |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
US8771966B2 (en) | 2010-06-03 | 2014-07-08 | Genentech, Inc. | Immuno-PET imaging of antibodies and immunoconjugates and uses therefor |
WO2011153346A1 (en) | 2010-06-03 | 2011-12-08 | Genentech, Inc. | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
WO2011156328A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP2933262A1 (en) | 2010-07-09 | 2015-10-21 | Affibody AB | Polypeptides |
WO2012004384A2 (en) | 2010-07-09 | 2012-01-12 | Affibody Ab | Polypeptides |
US10329331B2 (en) | 2010-07-09 | 2019-06-25 | Affibody Ab | Polypeptides |
EP2621538B1 (en) | 2010-09-28 | 2015-12-16 | Amylin Pharmaceuticals, LLC | Engineered polypeptides having enhanced duration of action |
WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
EP3575321A1 (en) | 2010-11-08 | 2019-12-04 | Ablynx N.V. | Cxcr2 binding polypeptides |
EP3578568A2 (en) | 2010-11-08 | 2019-12-11 | Ablynx N.V. | Cxcr2 binding polypeptides |
WO2012062713A1 (en) | 2010-11-08 | 2012-05-18 | Novartis Ag | Cxcr2 binding polypeptides |
WO2012074757A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
EP3514169A1 (en) | 2010-11-26 | 2019-07-24 | Molecular Partners AG | Designed repeat proteins binding to serum albumin |
WO2012069654A1 (en) | 2010-11-26 | 2012-05-31 | Molecular Partners Ag | Designed repeat proteins binding to serum albumin |
WO2012109624A2 (en) | 2011-02-11 | 2012-08-16 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
US9994639B2 (en) | 2011-03-28 | 2018-06-12 | Ablynx N.V. | Biological materials related to CXCR7 |
WO2012130874A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
WO2012156219A1 (en) | 2011-05-05 | 2012-11-22 | Ablynx Nv | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
EP3363815A1 (en) | 2011-05-05 | 2018-08-22 | Merck Patent GmbH | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
EP4105231A1 (en) | 2011-05-05 | 2022-12-21 | Merck Patent GmbH | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
WO2012155019A1 (en) | 2011-05-12 | 2012-11-15 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
WO2012163887A1 (en) | 2011-05-27 | 2012-12-06 | Ablynx Nv | Inhibition of bone resorption with rankl binding peptides |
WO2012175740A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Immunoglobulin single variable domains directed against ige |
US9487589B2 (en) | 2011-06-30 | 2016-11-08 | Genentech, Inc. | Anti-c-met-antibody formulations |
US9382305B2 (en) | 2011-07-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
WO2013004607A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
WO2013007563A1 (en) | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Fusion proteins releasing relaxin and uses thereof |
US9365619B2 (en) | 2011-08-24 | 2016-06-14 | Otsuka Chemical Co., Ltd. | IgG-binding peptide and method for detecting and purifying IgG using same |
WO2013027796A1 (en) | 2011-08-24 | 2013-02-28 | 大塚化学株式会社 | IgG-BINDING PEPTIDE AND METHOD FOR DETECTING AND PURIFYING IgG USING SAME |
WO2013043071A1 (en) | 2011-09-23 | 2013-03-28 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Modified albumin-binding domains and uses thereof to improve pharmacokinetics |
EP3311837A1 (en) | 2011-09-23 | 2018-04-25 | Ablynx NV | Prolonged inhibition of interleukin-6 mediated signaling |
WO2013043070A2 (en) | 2011-09-23 | 2013-03-28 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Anti-tumor necrosis factor-alpha agents and uses thereof |
WO2013045707A2 (en) | 2011-09-30 | 2013-04-04 | Ablynx Nv | Biological materials related to c-met |
US11135303B2 (en) | 2011-10-14 | 2021-10-05 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2013068571A1 (en) | 2011-11-11 | 2013-05-16 | Ucb Pharma S.A. | Albumin binding antibodies and binding fragments thereof |
US10023631B2 (en) | 2011-11-11 | 2018-07-17 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
US9803004B2 (en) | 2011-11-11 | 2017-10-31 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
WO2013112467A1 (en) | 2012-01-23 | 2013-08-01 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
WO2013128027A1 (en) | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
JP2020033372A (en) * | 2012-03-28 | 2020-03-05 | アフィボディ・アーベー | Oral administration |
WO2013143890A1 (en) | 2012-03-28 | 2013-10-03 | Affibody Ab | Oral administration |
JP2015512902A (en) * | 2012-03-28 | 2015-04-30 | アフィボディ・アーベー | Oral administration |
JP2018052961A (en) * | 2012-03-28 | 2018-04-05 | アフィボディ・アーベー | Oral administration |
WO2013168108A2 (en) | 2012-05-09 | 2013-11-14 | Novartis Ag | Chemokine receptor binding polypeptides |
US9884124B2 (en) | 2012-05-17 | 2018-02-06 | Extend Biosciences, Inc. | Carriers for improved drug delivery |
WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
US10155792B2 (en) | 2012-09-25 | 2018-12-18 | Affibody Ab | Albumin binding polypeptide |
US9931415B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2014057073A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
US10799596B2 (en) | 2012-10-12 | 2020-10-13 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-antibody conjugates |
US9889207B2 (en) | 2012-10-12 | 2018-02-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10335497B2 (en) | 2012-10-12 | 2019-07-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
US10722594B2 (en) | 2012-10-12 | 2020-07-28 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
EP2839860A1 (en) | 2012-10-12 | 2015-02-25 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10994023B2 (en) | 2012-10-12 | 2021-05-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11779650B2 (en) | 2012-10-12 | 2023-10-10 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11771775B2 (en) | 2012-10-12 | 2023-10-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
US11701430B2 (en) | 2012-10-12 | 2023-07-18 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10646584B2 (en) | 2012-10-12 | 2020-05-12 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11690918B2 (en) | 2012-10-12 | 2023-07-04 | Medimmune Limited | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
US10780181B2 (en) | 2012-10-12 | 2020-09-22 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10011641B2 (en) | 2012-10-25 | 2018-07-03 | Affibody Ab | ABD binding polypeptide |
US9745340B2 (en) | 2012-10-25 | 2017-08-29 | Affibody Ab | Method for the separation of proteins containing an albumin-binding |
WO2014064237A1 (en) | 2012-10-25 | 2014-05-01 | Affibody Ab | Abd binding polypeptide |
EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
US9790475B2 (en) | 2013-01-03 | 2017-10-17 | Covagen Ag | Human serum albumin binding compounds and fusion proteins thereof |
US10364419B2 (en) | 2013-01-03 | 2019-07-30 | Covagen Ag | Human serum albumin binding compounds and fusion proteins thereof |
WO2014106583A1 (en) | 2013-01-03 | 2014-07-10 | Covagen Ag | Human serum albumin binding compounds and fusion proteins thereof |
WO2014115229A1 (en) | 2013-01-28 | 2014-07-31 | 独立行政法人産業技術総合研究所 | Antibody-binding peptide |
US9605029B2 (en) | 2013-01-28 | 2017-03-28 | National Institute Of Advanced Industrial Science And Technology | Antibody-binding peptide |
WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
WO2014140358A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Research (Munich) Gmbh | Single chain binding molecules comprising n-terminal abp |
EP3653642A1 (en) | 2013-03-15 | 2020-05-20 | Amgen Research (Munich) GmbH | Single chain binding molecules comprising n-terminal abp |
WO2015023355A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10029018B2 (en) | 2013-10-11 | 2018-07-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015095223A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
WO2015095212A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
WO2015095227A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
US10167322B2 (en) | 2013-12-20 | 2019-01-01 | Affibody Ab | Engineered albumin binding polypeptide |
WO2015132248A3 (en) * | 2014-03-03 | 2016-01-14 | Vrije Universiteit Brussel (Vub) | Sequamers - a non-natural type of peptide libraries randomly constrained by their primary sequences |
WO2015139046A1 (en) | 2014-03-14 | 2015-09-17 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US10240207B2 (en) | 2014-03-24 | 2019-03-26 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with HGF expression |
KR20160145825A (en) * | 2014-04-30 | 2016-12-20 | 펀다시오 인스티튜트 드’인베스티가시오 바이오메티칼 드 벨리비티게 (아이디벨) | Adenovirus comprising an albumin-binding moiety |
US10604549B2 (en) | 2014-04-30 | 2020-03-31 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Adenovirus comprising an albumin-binding moiety |
US11578104B2 (en) | 2014-04-30 | 2023-02-14 | Fundació Institut D'lnvestigació Biomedica De Bellvitge (í DIBELL) | Adenovirus comprising an albumin-binding moiety |
EP2940128A1 (en) * | 2014-04-30 | 2015-11-04 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Adenovirus comprising an albumin-binding moiety |
KR102628234B1 (en) | 2014-04-30 | 2024-01-22 | 펀다시오 인스티튜트 드’인베스티가시오 바이오메티칼 드 벨리비티게 (아이디벨) | Adenovirus comprising an albumin-binding moiety |
WO2015166082A1 (en) * | 2014-04-30 | 2015-11-05 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | Adenovirus comprising an albumin-binding moiety |
US11124573B2 (en) | 2014-05-02 | 2021-09-21 | Janssen Biotech, Inc. | Compositions and methods related to engineered Fc constructs |
WO2015193452A1 (en) | 2014-06-18 | 2015-12-23 | Ablynx Nv | Kv1.3 binding immunoglobulins |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
WO2016040856A2 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP3235820A1 (en) | 2014-09-17 | 2017-10-25 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
US11000510B2 (en) | 2014-09-23 | 2021-05-11 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
US12016842B2 (en) | 2014-09-23 | 2024-06-25 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
US11116816B2 (en) | 2014-10-22 | 2021-09-14 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
US10406202B2 (en) | 2014-10-22 | 2019-09-10 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
US10702574B2 (en) | 2014-10-22 | 2020-07-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
US10420819B2 (en) | 2014-10-22 | 2019-09-24 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
US10208120B2 (en) | 2014-11-05 | 2019-02-19 | Genentech, Inc. | Anti-FGFR2/3 antibodies and methods using same |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2016090050A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
WO2016100803A2 (en) | 2014-12-19 | 2016-06-23 | Alexion Pharmaceuticals, Inc. | Methods of treating tissue calcification |
EP3967755A1 (en) | 2014-12-19 | 2022-03-16 | Alexion Pharmaceuticals, Inc. | Methods of treating tissue calcification |
WO2016156570A1 (en) | 2015-04-02 | 2016-10-06 | Ablynx N.V. | Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity |
WO2016164308A1 (en) | 2015-04-06 | 2016-10-13 | Subdomain, Llc | De novo binding domain containing polypeptides and uses thereof |
WO2016164305A1 (en) | 2015-04-06 | 2016-10-13 | Subdomain, Llc | De novo binding domain containing polypeptides and uses thereof |
EP3903804A1 (en) | 2015-04-06 | 2021-11-03 | Subdomain, LLC | De novo binding domain containing polypeptides and uses thereof |
US11702473B2 (en) | 2015-04-15 | 2023-07-18 | Medimmune Limited | Site-specific antibody-drug conjugates |
US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
WO2016180969A1 (en) | 2015-05-13 | 2016-11-17 | Ablynx N.V. | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
EP4345112A2 (en) | 2015-05-13 | 2024-04-03 | Ablynx N.V. | T cell recruiting polypeptides based on cd3 reactivity |
WO2016180982A1 (en) | 2015-05-13 | 2016-11-17 | Ablynx N.V. | T cell recruiting polypeptides based on cd3 reactivity |
EP3611192A2 (en) | 2015-05-13 | 2020-02-19 | Ablynx N.V. | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
US11208452B2 (en) | 2015-06-02 | 2021-12-28 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
US11292825B2 (en) | 2015-10-01 | 2022-04-05 | Novo Nordisk A/S | Protein conjugates |
EP3932945A1 (en) | 2015-11-27 | 2022-01-05 | Ablynx NV | Polypeptides inhibiting cd40l |
US10392393B2 (en) | 2016-01-26 | 2019-08-27 | Medimmune Limited | Pyrrolobenzodiazepines |
US11517626B2 (en) | 2016-02-10 | 2022-12-06 | Medimmune Limited | Pyrrolobenzodiazepine antibody conjugates |
US10695439B2 (en) | 2016-02-10 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2017151707A1 (en) | 2016-03-01 | 2017-09-08 | The Board Of Trustees Of The University Of Illinois | L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability |
EP4273551A2 (en) | 2016-03-25 | 2023-11-08 | F. Hoffmann-La Roche AG | Multiplexed total antibody and antibody-conjugated drug quantification assay |
WO2017165734A1 (en) | 2016-03-25 | 2017-09-28 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
US10543279B2 (en) | 2016-04-29 | 2020-01-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer |
US11623964B2 (en) | 2016-05-23 | 2023-04-11 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered Fc constructs |
US11155640B2 (en) | 2016-05-23 | 2021-10-26 | Janssen Biotech, Inc. | Compositions and methods related to engineered Fc constructs |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
WO2017218786A1 (en) | 2016-06-16 | 2017-12-21 | Alexion Pharmaceuticals, Inc. | Methods of treating myointimal proliferation |
EP3827835A1 (en) | 2016-06-16 | 2021-06-02 | Inozyme Pharma, Inc. | Methods of treating myointimal proliferation |
WO2018007442A1 (en) | 2016-07-06 | 2018-01-11 | Ablynx N.V. | Treatment of il-6r related diseases |
WO2018029182A1 (en) | 2016-08-08 | 2018-02-15 | Ablynx N.V. | Il-6r single variable domain antibodies for treatment of il-6r related diseases |
US11008365B2 (en) | 2016-09-01 | 2021-05-18 | National Institute Of Advanced Industrial Science And Technology | Polypeptide exhibiting affinity to antibodies forming non-native three-dimensional structure |
WO2018050833A1 (en) | 2016-09-15 | 2018-03-22 | Ablynx Nv | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
EP3521300A4 (en) * | 2016-09-30 | 2019-12-25 | FUJIFILM Corporation | Cyclic peptide, affinity chromatography carrier, labeled antibody, antibody-drug conjugate, and pharmaceutical preparation |
EP4043479A1 (en) * | 2016-09-30 | 2022-08-17 | FUJIFILM Corporation | Cyclic peptide, affinity chromatography support, labeled antibody, antibody-drug conjugate, and pharmaceutical preparation |
US11066446B2 (en) | 2016-09-30 | 2021-07-20 | Fujifilm Corporation | Cyclic peptide, affinity chromatography support, labeled antibody, antibody drug conjugate, and pharmaceutical preparation |
CN109790202A (en) * | 2016-09-30 | 2019-05-21 | 富士胶片株式会社 | Cyclic peptide, affinity chromatography carrier, labelled antibody, antibody drug complex and pharmaceutical preparation |
US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2018091606A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
US11220531B2 (en) | 2017-01-06 | 2022-01-11 | Janssen Biotech, Inc. | Engineered Fc constructs |
US11827682B2 (en) | 2017-01-06 | 2023-11-28 | Momenta Pharmaceuticals, Inc. | Engineered Fc constructs |
US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US11813335B2 (en) | 2017-02-08 | 2023-11-14 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11471537B2 (en) | 2017-04-05 | 2022-10-18 | Novo Nordisk A/S | Oligomer extended insulin-Fc conjugates |
US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
WO2018199337A1 (en) | 2017-04-28 | 2018-11-01 | 味の素株式会社 | Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof |
WO2018220234A1 (en) | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Adamts binding immunoglobulins |
WO2018220236A1 (en) | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Polypeptides binding adamts5, mmp13 and aggrecan |
EP4272822A2 (en) | 2017-06-02 | 2023-11-08 | Merck Patent GmbH | Adamts binding immunoglobulins |
WO2018220225A1 (en) | 2017-06-02 | 2018-12-06 | Ablynx Nv | Aggrecan binding immunoglobulins |
WO2018220235A1 (en) | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Mmp13 binding immunoglobulins |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
US11938192B2 (en) | 2017-06-14 | 2024-03-26 | Medimmune Limited | Dosage regimes for the administration of an anti-CD19 ADC |
WO2019014360A1 (en) | 2017-07-11 | 2019-01-17 | Alexion Pharmaceuticals, Inc. | Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof |
US11642416B2 (en) | 2017-08-09 | 2023-05-09 | Massachusetts Institute Of Technology | Albumin binding peptide conjugates and methods thereof |
WO2019032952A1 (en) | 2017-08-11 | 2019-02-14 | The Board Of Trustees Of The University Of Illinois | Truncated guinea pig l-asparaginase variants and methods of use |
US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2019067502A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) |
WO2019072868A1 (en) | 2017-10-10 | 2019-04-18 | Numab Therapeutics AG | Multispecific antibody |
WO2019099440A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Multifunctional immune cell therapies |
US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
WO2019240288A1 (en) | 2018-06-14 | 2019-12-19 | 味の素株式会社 | Substance having affinity for antibody, and compound or salt thereof having bioorthogonal functional group |
EP4406975A2 (en) | 2018-06-14 | 2024-07-31 | Ajinomoto Co., Inc. | Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof |
WO2020090979A1 (en) | 2018-10-31 | 2020-05-07 | 味の素株式会社 | Compound comprising substance with affinity for antibody, cleavage site and reactive group, or salt thereof |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
WO2021089609A1 (en) | 2019-11-04 | 2021-05-14 | Numab Therapeutics AG | Multispecific antibody |
EP3816185A1 (en) | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
WO2021123186A1 (en) | 2019-12-20 | 2021-06-24 | UCB Biopharma SRL | Multi-specific antibody with binding specificity for human il-13 and il-17 |
WO2021239987A1 (en) | 2020-05-29 | 2021-12-02 | Numab Therapeutics AG | Multispecific antibody |
EP3915580A1 (en) | 2020-05-29 | 2021-12-01 | Numab Therapeutics AG | Multispecific antibody |
WO2022004805A1 (en) | 2020-06-30 | 2022-01-06 | 株式会社ガイアバイオメディシン | Method for stabilizing binding of antibody to nk cell and use thereof |
EP3988568A1 (en) | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
WO2022084440A2 (en) | 2020-10-21 | 2022-04-28 | Numab Therapeutics AG | Combination treatment |
WO2022098745A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
US11733246B2 (en) | 2020-11-03 | 2023-08-22 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1) |
US11766414B2 (en) | 2020-11-03 | 2023-09-26 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
WO2022122654A1 (en) | 2020-12-07 | 2022-06-16 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
WO2022167460A1 (en) | 2021-02-02 | 2022-08-11 | Numab Therapeutics AG | Multispecific antibodies having specificity for ror1 and cd3 |
WO2022178255A2 (en) | 2021-02-19 | 2022-08-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies that neutralize sars-cov-2 |
WO2023089107A1 (en) | 2021-11-19 | 2023-05-25 | Medizinische Hochschule Hannover | Novel sars-cov-2 neutralizing antibodies |
EP4183800A1 (en) | 2021-11-19 | 2023-05-24 | Medizinische Hochschule Hannover | Novel sars-cov-2 neutralizing antibodies |
WO2024008904A2 (en) | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
WO2024038095A1 (en) | 2022-08-16 | 2024-02-22 | Iome Bio | NOVEL ANTI-RGMb ANTIBODIES |
WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
Also Published As
Publication number | Publication date |
---|---|
EP1240337A2 (en) | 2002-09-18 |
EP1240337B1 (en) | 2006-08-23 |
CY1106236T1 (en) | 2011-06-08 |
US20040253247A1 (en) | 2004-12-16 |
ATE422369T1 (en) | 2009-02-15 |
DE60041564D1 (en) | 2009-03-26 |
PT1240337E (en) | 2007-01-31 |
AU2006202341B2 (en) | 2009-02-19 |
DE60030323T2 (en) | 2007-10-11 |
JP5004640B2 (en) | 2012-08-22 |
AU2458701A (en) | 2001-07-03 |
ES2270893T3 (en) | 2007-04-16 |
US20070160534A1 (en) | 2007-07-12 |
JP2003518075A (en) | 2003-06-03 |
DK1240337T3 (en) | 2007-01-02 |
AU784285B2 (en) | 2006-03-02 |
CA2390691A1 (en) | 2001-06-28 |
CA2921260A1 (en) | 2001-06-28 |
AU2009201933B2 (en) | 2013-01-10 |
JP4949132B2 (en) | 2012-06-06 |
US7608681B2 (en) | 2009-10-27 |
JP2007289187A (en) | 2007-11-08 |
ATE337403T1 (en) | 2006-09-15 |
EP2180054A1 (en) | 2010-04-28 |
AU2009201933A1 (en) | 2009-06-04 |
US7635749B2 (en) | 2009-12-22 |
DE60030323D1 (en) | 2006-10-05 |
CA2390691C (en) | 2016-05-10 |
WO2001045746A3 (en) | 2001-10-11 |
JP2007289200A (en) | 2007-11-08 |
AU2006202341A1 (en) | 2006-06-29 |
US20100121039A1 (en) | 2010-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7608681B2 (en) | Methods and compositions for prolonging elimination half-times of bioactive compounds | |
JP2007289187A5 (en) | ||
US20160185874A1 (en) | Serum albumin binding peptides for tumor targeting | |
US20070020264A1 (en) | Serum albumin binding peptides for tumor targeting | |
US20060228364A1 (en) | Serum albumin binding peptides for tumor targeting | |
CA2286397C (en) | Humanized antibodies and methods for forming humanized antibodies | |
JP2003518075A5 (en) | ||
CN114828895A (en) | Method for preparing eribulin-based antibody-drug conjugates | |
CN117120476A (en) | Antibodies specific for structurally disordered sequences | |
CN113045659B (en) | anti-CD73 humanized antibodies | |
EP1757311B1 (en) | Methods and compositions for prolonging elimination half-times of bioactive compounds | |
EP1203014B1 (en) | Peptide antagonists of factor viia | |
CN115160434A (en) | Humanized single domain antibody and application and medicament thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 24587/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2390691 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10149835 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 546685 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000988373 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000988373 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000988373 Country of ref document: EP |